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ABSTRACT
MICHAEL DUNCAN: Biological and Chemoenzymatic Synthesis of Anticoagulant Heparan 
Sulfate
(Under the direction of Jian Liu)
    Heparan sulfate (HS) is a linear, heterogeneously sulfated polysaccharide that is ubiquitous 
to most mammalian tissues.  The roles played by HS on the cell surface and in the 
extracellular matrix (ECM) are diverse in function.  A number of HS/protein interactions 
have been studied and have led to a more detailed understanding of signal transduction 
pathways, enzyme activation, and ligand presentation.  Accumulating evidence has supported 
the role of the fine structure of HS in high-affinity interactions with serine protease 
inhibitors, growth factors, and microbial coat proteins.  These findings have led to a great 
deal of interest in understanding how specific HS structures are generated and the 
mechanisms that regulate HS biosynthesis.  
    Complex HS sequences are generated by a number of biosynthetic enzyme families, 
including the N-deacteylase N-sulfotransferases, epimerase, 2-O-, 6-O-, and 3-O-
sulfotransferases.  Herein, studies are presented that explore the functions of N-deacetylase 
N-sulfotransferase and the 3-O-sulfotransferases.  In addition, we report a chemoenzymatic 
approach to synthesizing anticoagulant heparin, a structural analogue of HS. The 
anticoagulant effects of heparin, derived from natural sources, have been exploited in the 
clinic for over seventy years.  A synthetic approach to heparin production could provide the 
anticoagulant with reduced side effects.  It would also allow for the investigation of other 
iii
therapeutic benefits of heparin and HS.  In conclusion, the work presented herein provides 
detail into the biosynthetic machinery and biological properties of HS, as well as strategies to 
control the assembly of heparin and HS polysaccharides.
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CHAPTER I. INTRODUCTION
Heparan Sulfate Structure, Biosynthesis, and Biological Functions
Heparan sulfate proteoglycans (HSPGs) consist of a core protein with one or more 
covalently attached glycosaminoglycan (GAG) chains.  These molecules are present on the 
cell surface and within extracellular matrices (ECM) including basement membranes.  
Traditionally, proteoglycans were thought to maintain the structural integrity of the ECM. 
However, over the past several decades it has been realized that these molecules play a 
variety of roles in both normal and pathophysiologic processes (Bernfield et al., 1999; 
Sasisekharan et al., 2002; Zak et al., 2002).  Some broadly defined functions of heparan 
sulfate (HS) include promoting ligand receptor interactions (Park et al., 2000b), attachment 
and entry receptor roles in microbial pathogenesis (Liu and Thorp, 2002; Wadstrom and 
Ljungh, 1999), and producing chemotactic gradients via interactions with chemokines and 
cytokines (Gotte, 2003). The polysaccharide unit of HSPGs is composed of 50 to 200
disaccharide units containing glucuronic acid (GlcA) 1,4 linked to N-acetylated 
glucosamine (GlcNAc).  This polysaccharide backbone undergoes extensive sulfonation 
reactions forming a mature HS chain (Esko and Selleck, 2002). 
Physio-chemical properties of HS and heparin- As depicted in Figure 1, uronic acid may 
be sulfated at the C2 position while glucosamine may carry sulfuryl groups at the C6, C3 or 
N2 position. The N2 position of glucosamine may also be unsubstituted, existing as
2primary amine.  Additional structural diversity  of HS is achieved through epimerization of 
GlcA to iduronic acid (IdoA) residues.  Heparin is a structural analogue of HS.  The primary
differences between heparin and HS are that heparin contains more IdoA residues and it is 
more highly sulfated.  Also, heparin is produced exclusively by connective tissue mast cells 
while HS is produced by most metazoan cell types.  
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Figure 1.  Disaccharide repeating units of heparan sulfate and heparin.  Sulfonation (R= -SO3) at Carbon 6 
(known as 6-O-sulfo glucosamine) of glucosamine is common.  Sulfonation at Carbon-2 of iduronic acid 
(known as 2-O-sulfo iduronic acid) is common.  Sulfonation at Carbon-3 of glucosamine (known as 3-O-sulfo 
glucosamine) is rare.  Both N-acetyl (R’=acetyl, GlcNAc) and N-sulfo glucosamine (R’= -SO3, GlcNS) are 
common.  N-unsubstituted glucosamine (R’ = -H, GlcNH2) is a low abundance component.
NMR and molecular modeling studies of heparin summarized in Figure 2A, reveal that it 
is a helical molecule in which its various sulfuryl groups project in an outward fashion
(Mulloy et al., 1993).  There appears to be little to no tertiary structure in heparin which 
allows the sulfo and carboxylate groups to display in relatively defined patterns.  In a recent 
study on the dynamics of heparin oligosaccharides, it was determined that the flexibility of 
the saccharide molecule is reduced as the sulfuryl group content  of the molecule increases
(Angulo et al., 2005).  This should have important implications for the way in which heparin 
binds to its various target proteins.  Additionally, modifications of the heparin backbone also 
3dictate the conformation of individual monosaccharide units.  For example, IdoA displays 
low energy equilibrium between two conformations, skew boat (2S0) and chair (1C4) [for 
reviews on HS and heparin structure see (Capila and Linhardt, 2002; Gama and Hsieh-
Wilson, 2005; Noti and Seeberger, 2005)].  
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Figure 2. Structure of heparin oligosaccharides. (A) The NMR and molecular modeling of a heparin based 
oligosaccharide reveals that the molecule has a helical structure in which the sulfate groups are pointing 
outward in a recurring pattern. (B) The iduronic acid residue of HS is in equilibrium between a chair and skew 
boat conformation.  The Reducing End (RE) and Nonreducing End (NRE) are indicated. Figure adapted from 
(Capila and Linhardt, 2002).
4Both conformations of the uronic acid residue have been observed in co -crystal and NMR 
based structural analysis of heparin/protein interactions (Faham et al., 1996; Hricovini et al., 
2001; Moon et al., 2004).  These results suggest that the HS binding domain of a target 
protein can accommodate either conformation of the uronic residue.
Important HS Protein Interactions
Growth Factors- Growth factors are a large family of cytokines involved in regulating cell 
growth, proliferation, and differentiation (for a review see (Dailey et al., 2005)).  There are 
22 forms of fibroblast growth factors (FGFs) and 5 FGF receptors (FGFRs). The FGFRs are 
receptor tyrosine kinases and are responsible, in part, for initiating cell signaling cascades.  It 
has been established that both FGF and FGFRs bind to heparin, and cell based studies have 
demonstrated that the interaction between these molecules is essential for FGF mediated cell 
signaling (Rapraeger et al., 1991; Yayon et al., 1991).
Two crystal structures of the FGF, heparin, and FGFR ternary complex have been solved 
(Pellegrini et al., 2000; Schlessinger et al., 2000).  Figure 3 displays an overview of the two 
structures. In the 2:2:2 complex referred to as the “two end model”, two heparin molecules 
make extensive contacts with one FGF (green) and one FGFR molecule (orange). Each  
heparin molecule also makes additional contact with the second FGFR.  In the second 
structure an “asymmetric” 2:2:1 stoichiometry was observed.  Here a single heparin molecule 
makes contact with two FGF molecules and only one FGFR.  The stark differences between 
the structures could reflect unique binding modes between different FGFs and FGFRs since 
different subtypes of each were used.  Given the task to assess which structure is 
5Figure 3. Two binding modes of the FGF:FGFR:heparin interaction. Two crystal structures of FGF and 
FGR in a complex with HS have been resolved.  The FGF molecule is pictured in green, FGFR in orange, and 
heparin in white (carbon atom), blue (nitrogen atom), yellow (sulfur), and oxygen (red).
6biologically relevant, it would appear that the two end model would put the two FGFR 
molecules in close proximity which could promote receptor dimerization.  It is well 
established that the FGF mediated signaling cascades that are initiated by receptor tyrosine 
kinases undergo trans autophosphorylation, thus two FGFRs  that are adjacent to one another 
may reflect a more relevant structure (Mohammadi et al., 2005a; Mohammadi et al., 2005b).
Antithrombin- Antithrombin (AT) is a serine protease inhibitor that plays an essential role 
in regulation of the blood coagulation cascade. This glycoprotein inhibits the activity of 
several late stage serine proteases of the cascade including factor Xa and thrombin.   The 
mechanism of inhibition involves the allosteric activation of AT.  As shown in Figure 4, the 
active form of AT presents an amino acid P1 loop that serves as a substrate for the serine 
protease.  When the loop is cleaved, AT undergoes a dramatic conformational change that 
leaves the serine protease covalently attached to AT as an acyl-enzyme intermediate and 
rendered inactive. AT activation proceeds through binding the cofactors heparin or HS.
The role of heparin and endothelial HS in the acceleration of AT activity has been studied 
extensively (Desai et al., 1998; Jin et al., 1997; Rosenberg et al., 1980; Rosenberg et al., 
1997).  HS increases the affinity of antithrombin (AT) for factor Xa and thrombin by 
approximately 1,000-fold, which in turn inhibits proteolytic activity and prevents formation 
of a blood clot.  Antithrombin binding HS and heparin contain a structurally defined 
antithrombin-binding site; a pentasaccharide with the structure –GlcNS(or Ac)6S-GlcUA-
GlcNS3S±6S-IdoUA2S-GlcNS6S- shown in Figure 5 (Atha et al., 1985).  Within the HS 
binding site, the 3-O-sulfated glucosamine residue (GlcNS3S±6S) is essential for binding to 
AT.  This single modification enhances binding affinity (Kd) by 10,000 fold.  Crystal 
7structures of AT in complex with the HS pentasaccharide reveal that hydrogen bonds are 
made with the carboxylate groups of hexuronic acid and the 6-O- and 3-O- sulfo groups of 
glucosamine.  Interestingly, the AT molecule does not make contact with 2-O-sulfo groups of
iduronic acid. This finding is further supported by an analysis of AT binding of HS devoid of 
2-O-sulfation (Zhang et al., 2001b).  In the absence of 2-O-sulfation, the binding affinity of 
anticoagulant HS for AT shows a slight increase.  
    The physiologic importance of HS mediated activation of AT is underscored by the severe
thrombotic phenotypes observed in patients that carry genetic mutations of AT that affect HS 
binding (Boyer et al., 1986; Koide et al., 1984; van Boven and Lane, 1997).  The endogenous 
AT binding pentasaccharide is an essential component of clinically used anticoagulant Low 
Molecular Weight Heparin (LWMH) and is the structural the basis for the FDA approved 
drug Arixtra. 
Figure 4.  The allosteric activation of AT by the high affinity HS derived pentasaccharide. The AT binding 
pentasaccharide induces a conformational change in the protein that exposes its reactive loop which exposes an 
arginine residue.  This loop serves as a suicide substrate for the serine proteases factor Xa and thrombin. Figure 
modified from (Johnson and Huntington, 2003)
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Figure 5. The high affinity AT-binding HS pentasaccharide. The R’ represents sulfuryl (-OSO3H) or acetyl 
(-COCH3) groups and R represents hydrogen (-H) or a sulfuryl group.  The essential 3-O-sulfated glucosamine 
residue is highlighted in red.
Thrombin- Thrombin, one of the late stage serine proteases of the blood coagulation 
cascade, plays essential regulatory roles in the balance between procoagulant and 
anticoagulant states. The molecular targets of thrombin are manifold in function (Huntington, 
2005).  Fibrinogen is the precursor of the blood clot constituent fibrin.  Protein C, an 
anticoagulant factor, is activated by thrombin and forms a complex with additional factors to 
inhibit activation of thrombin and factor X, another member of the blood coagulation 
cascade.  Additionally, thrombin serves a role in the positive regulatory feedback loop of the 
coagulation cascade.  Thrombin can activate the early serine proteases Factors XII, VIII, and 
V, leading to subsequent activation of prothrombin to thrombin.  The mechanisms which 
dictate recognition of various substrates in part is dependent upon cofactor binding.  One 
such cofactor is heparin.  Crystallographic studies have shown that two cationic patches 
(exosites I and II) exist on the surface of thrombin that could serve as a heparin binding 
domain. Site directed mutagenesis (Gan et al., 1994; Sheehan and Sadler, 1994; Ye et al., 
1994) and a co-crystal structure of thrombin bound to a highly sulfated hexasaccharide 
fragment reveals that heparin binds to exosite II (Carter et al., 2005).  The interaction appears 
to be nonspecific in nature since heparin was observed to bind thrombin in at least two 
distinct orientations as shown in Figure 6A.  
9Figure 6. Crystal structure of heparin bound to thrombin.  In (A) two distinct binding modes of a heparin 
hexasaccharide bridge two molecules of thrombin together; molecule AB with GH and CD with EF. A 
stereoview of the electrostatic potential diagram (B) depicts the heparin binding pocket of thrombin that is lined 
with basic arginine and lysine amino acid residues. This figure was adapted from (Carter et al., 2005).
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Heparin binding is highly dependent on salt bridge formation between the negatively 
charged sulfuryl groups of the oligosaccharide and positively charged residues of basic 
amino acids of the protein some of which are depicted in Figure 6B.  Based on the co-crystal 
structure and mutagenesis studies, the authors outline several amino acid residues that are 
critical for binding.  Arg93 interacts with a 6-O-sulfuryl group via a salt bridge.  Lys236 
makes ionic contacts with the carboxylate and 2-O-sulfuryl groups of IdoA . Lys240 forms a 
salt bridge with a 6-O-sulfryl group or an N-sulfu ryl group depending on the orientation of 
the heparin molecule.  Arg101 can make ionic and/or hydrogen bonds with a 6-O-sulfryl 
group or an N-sulfuryl gro up depending on the mode of heparin binding. 
AT-mediated deactivation of thrombin is dependent on HS and heparin acting as a bridge 
between the protease and inhibitor.  One limitation of using the pentasaccharide-based 
Arixtra anticoagulant is that it is insufficiently long enough to form this bridge. 
Understanding the manner in which thrombin and heparin interacts should provide a great 
deal of insight on how to build anticoagulant heparin analogues that may be more effective in 
preventing and treating thrombotic events.   
Chemokines- Virtually all chemokines bind to HSPGs, forming an interaction that is 
critical for the function of these small protein signaling molecules (Handel et al., 2005).  
Chemokines associate with cell surface HSPGs in order to generate concentration gradients 
on endothelial cells (Kuschert et al., 1999). This is an essential process in the immune 
response because it directs leukocytes to their site of action.  HSPGs also enhance the half-
life of chemokines by protecting them from protease digestion (Sadir et al., 2004).  Indeed, 
the expression of HSPG biosynthetic enzymes and HSPG synthesis is enhanced in concert 
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with the immunologic response (Carter et al., 2003).  HSPGs may also promote 
oligomerization which can provide high local concentrations of the chemokine to promote 
signaling via their cognate chemokine receptor(s) (Hoogewerf et al., 1997).  
Several reports that characterize heparan sulfate that binds to chemokines have led to a 
proposed oligosaccharide structural motif essential for inducing chemokine dimerization
(Stringer et al., 2002).  In the HS structure, two N-sulfated domains (a hexasaccharide or 
greater) are bridged by a nonsulfated spacer region.  The lack of sulfation of the linker group 
could provide flexibility in the HS molecule allowing it to wrap around two chemokine 
molecules.  Structural analysis of the binding site of macrophage inflammatory protein-1
(MIP-1) on heparan sulfate reveals that the nonsulfated linker region is protected from 
enzymatic cleavage, supporting this model (Stringer et al., 2002).  Additionally, the types of 
O-sulfation and the size of the N-sulfo domains of chemokine binding HS vary.  Several 
examples of this binding mode have been reported (Spillmann et al., 1998; Stringer et al., 
2002; Stringer and Gallagher, 1997). 
Platelet factor 4 (PF4) is the most highly abundant chemokine secreted by platelets.  It is a
CXC type chemokine and plays roles in a variety of physiologic processes.  For example, this 
molecule is involved in the inhibition of angiogenesis, neutrophil adhesion, and the 
promotion of anticoagulant activity by protein C (Slungaard, 2005).  PF4 binds to heparin 
and HSPGs and this complex is associated with thrombocytopenia, a troubling side effect of 
heparin treatment.  Heparin Induced Thrombocytopenia (HIT)  is a severe immunologic 
response initiated by antibodies formed against the heparin PF4 complex (Arepally and 
Cines, 2002).  A structural analysis of HS that binds to PF4 by Gallagher and coworkers 
reveals that PF4 binds to a sequence of the HS polysaccharide that is enriched with iduronic 
12
acid and 2-O-sulfation (Stringer and Gallagher, 1997).  The saccharide structure is composed 
of three motifs; two tetradecasaccharide N-sulfo domains that carry the 2-O-sulfo iduronic 
acid residues, and a single N-acetylated domain of 16 saccharide units in length.  Linhardt 
and co-workers demonstrated that a highly sulfated dodecasaccharide binds to PF4 and 
triggers structural changes (Mikhailov et al., 1999).
Interleukin 8 (IL-8) is a 72 amino acid CXC chemokine produced by a wide variety of cell 
types including macrophages and monocytes.  It is a critical component in the acute 
inflammatory response, functioning as a chemotactic factor in neutrophil migration
(Middleton et al., 1997).  Studies have demonstrated that the interaction between IL8 and 
HSPGs (as well as chondroitin sulfate proteoglycans) is essential to its localization in lung 
tissues (Frevert et al., 2003).  Structural analyses reveal that the IL-8 binding site on HSPGs 
is composed of two hexasaccharide N-sulfo domains that contain 2-O- and 6-O-sulfated 
iduronic acid and glucosamine units, respectively (Spillmann et al., 1998).  
Differences in the unique structural requirements by chemokines for their HS binding sites 
underscore the importance of the mechanisms by which HS biosynthetic machinery control 
HS sequence.   
Herpes Simplex Virus 1 glycoprotein D- Herpes simplex virus 1 (HSV1) is a member of 
the large Herpesviridae family of DNA viruses.  The pathology associated with HSV1 
infection includes formation of lesions typically in or near the mouth, cornea, and less 
frequently on genital tissues (Corey and Spear, 1986).  The HSV1 virion is encased in a lipid 
envelope that contains at least 12 glycoproteins (Shukla and Spear, 2001).  Several of these 
glycoproteins have been shown to mediate two essential processes in viral pathogenesis 
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(Spear, 2004). The attachment of the virion to the host cell surface proceeds through 
glycoproteins gB and gC, which are known to bind to cell surface HSPGs.  Viral entry into a 
host cell is dependent upon the interactions between another envelope glycoprotein, gD, and 
its receptor on the host cell surface. In 1999, it was shown that cell surface HSPGs carrying 
specific 3-O-sulfated polysaccharide structures could serve as entry receptors for HSV1 
through their interactions with gD (Shukla et al., 1999).  An example of the viral entry assay 
is shown in Figure 7.  The Herpes Virus Entry Mediator (HVEM) of the Tumor Necrosis 
Factor  (TNF) receptor superfamily as well as nectin 1 and 2 of the immunoglobulin 
receptor superfamily and 3-O-HS can also function as HSV1 entry receptors (Spear et al., 
2000).  Notably, the 3-O-HS polysaccharide entry receptor has a similar binding affinity for 
Figure 7. Entry of HSV-1 into Chinese hampster ovary (CHO-K1) cells and transfected CHO-K1 cells. CHO-
K1 cells were transfected with control plasmid (A) or with pcDNA3.1-3OST5 (B). At 36 h after transfection, the 
cells were exposed to KOS-gL86 at 100 plaque-forming units/cell. Six hours later, the cells were washed, fixed, 
and incubated with X-gal to identify infected cells (dark cells). Figure from (Xia et al., 2002)
gD as do the HSV1 protein entry receptors.  These initial findings led to the structural 
characterization of a gD-binding HS octasaccahride that carries the essential 3-O-sulfate 
group depicted in Figure 8A (Liu et al., 2002). The 3-O-sulfuryl group occurs within a highly 
sulfated domain on a rarely observed N-unsubstituted glucosamine residue.
A gD crystal structure and extensive mutagenesis studies have established that the heparan 
sulfate binding domain is located in the N-terminal ectodomain of this transmembrane 
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protein (Carfi et al., 2001; Yoon and Spear, 2004; Yoon et al., 2003).  The HVEM and nectin 
2 receptors are also sensitive to mutations in the N-terminal ectodomain of gD (Yoon et al., 
2003).  A strategy to blockade this region in the ectodomain of gD may prove useful in 
inhibiting viral entry via these two unique receptors.  One such strategy is to use HS 
analogues to block viral entry.  The gD-binding octasaccharide characterized by Liu and co-
workers binds with low micromolar affinity (Liu et al., 2002) and structural analogues are 
being synthesized and tested in cell based assays as an HSV1 entry inhibitor.    
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Figure 8.  The structure of gD-binding octasaccharide purified from a HS derived library. (A) 
This molecule contains the three functional groups at the N position including the sulfuryl, acetyl, and 
primary amine. The octasaccharide was purified from a 3-O-sulfonated oligosaccharide HS library.  As 
shown in (B) the purity of the octasaccharide was >80% based on analysis by capillary electrophoresis
(adapted from (Liu et al., 2002)). 
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HS Biosynthetic Pathway
    Core proteins- A variety of core proteins, which carry covalently linked GAGs and present 
them in their biological context have been identified (Hacker et al., 2005; Iozzo, 2005).  
These core proteins can be categorized into two groups.  Soluble core proteins are secreted 
into the extracellular matrix, while cell surface core proteins are integrated into cell 
membranes1.  A list of core proteins and their cellular locale is presented in Table I.  Once 
the core protein has been synthesized, it undergoes a variety of post-translational 
modifications, including GAG assembly that may be classified into three steps; linkage 
region synthesis, chain polymerization, and chain modification (Esko and Selleck, 2002).
Table 1. Core Proteins and their biological location
Core Protein
(# of isoforms)
Location
Syndecana Cell surface
Glypicanb Cell surface
Perlecanc ECM, basement membranes
Serglycind Mast Cells
Agrin ECM, Basement Membranes
Collagen XVIII ECM Basement Membranes
a. Expressed as type I membrane proteins that may be cleaved by extracellular 
proteases 
b. Expressed as Glycosylphosphotidylinositol anchored proteins and may be cleaved by 
GPIases. 
c. A modular protein that has at least 5 functional domains.
d. The core protein of heparin. The protein component is cleaved before a mature 
heparin molecule is formed
Step One: GAG Linkage Region Synthesis
The GAG linkage region of CS and HS proteoglycans consists of the tetrasaccharide 
GlcA1,3Gal1,3Gal1,4Xyl that is O-linked to serine residues (Figure 9) of the core 
1Cell surface HSPGs may also be released into the extracellular matrix.  See Table I for details.
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protein. The glycosyltransferases that synthesize this oligosaccharide are ubiquitously 
expressed in eukaryotic cells (Sugahara and Kitagawa, 2002).  The formation of the linkage 
region is essential for GAG assembly and may dictate the type of GAG that will be extended. 
O
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Figure 9. The proteoglycan tetrasaccharide linkage region. The tetrasaccharide is composed of glucuronic
acid1,3 linked to galactose 1,3 linked to galactose 1,4 linked to xylose  linked to a serine residue of the 
core protein.  The blue arrows indicate potential sulfation sites while the red arrow indicates the potential 
position for phosphorylation. 
Xylosyltransferase- Two isoforms of human xylosyltransferase with 55% identity to one 
another have been cloned from JAR choriocarcinoma cells (Gotting et al., 2000). Enzymatic 
activity for XylT-I has been verified. With UDP-xylose as a sugar donor, XylT-I glycosylates 
serine residues contained in the Ser-Gly- X (where X can be any amino acid residue) peptide 
consensus sequence (Brinkmann et al., 1997).  Studies of a XylT-I negative CHO cell line 
indicate that this enzyme performs the rate limiting step in HS and CS/dermatin sulfate (DS)
proteoglycan GAG linker region synthesis (Esko et al., 1985).  Core protein xylosylation has 
been reported to take place in the pre-Golgi complex (Kearns et al., 1993).  Studies have also 
shown that XylT-I is primarily secreted into the extracellular matrix (Gotting et al., 1999). 
The release of XylT-I from the Golgi complex and its relevance in an extracellular context 
have yet to be determined.
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Galactosyltransferase- The galactosyltransferase I transfers galactose to O-linked 
xylosylproteins (Okajima et al., 1999) generating a 14 linkage while galactosyltransferase 
II preferentially catalyzes the formation of Gal13Gal linkages (Bai et al., 2001).  Both of 
these enzymes belong to the six member 1,3-Galactosyltransferase family and are type II 
membrane bound proteins localized to the medial Golgi complex. GalTII is the only member 
of this family that recognizes terminal galactose residues.  siRNA silencing experiments in 
cell culture demonstrate that it is an essential component of the GAG biosynthetic pathway 
(Bai et al., 2001).
Glucuronyltransferase- In the final step of GAG linkage region biosynthesis the 
Glucuronyltransferase I catalyzes formation of the 13 linkage between GlcA and 
Gal1,4Gal1,4Xyl1-O-Ser (Kitagawa et al., 1998).  The resultant tetrasaccharide serves as 
a substrate for both N-acetylglucosaminyltransferase as well as N-acetyl 
galactosaminyltransferase. Modification by GlcNAcT initiates HS polysaccharide synthesis 
while GalNAcT initiates the synthesis of CS and DS polysaccharides.  Studies have 
demonstrated that the substrate selectivity of these enzymes may be dictated by regio-
selective phosphorylation of the xylose residue (2-O-phosphoryl xylose) and/or sulfonation at 
the 4- and 6-hydroxyl position of the internal and/or external galactose residues of the GAG 
linkage region (Gulberti et al., 2005).  Sulfonation of the tetrasaccharide linker increases 
catalytic efficiency of GlcATI, suggesting that this modification may promote GAG 
polysaccharide elaboration.  Structural analysis of GAGs isolated from syndecan 1 of 
cultured NMuMG (normal murine mammary gland) cells revealed that sulfated galactose 
residues contained in the linker tetrasaccharide were only observed in CS and DS GAGs 
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whereas C2 phosphorylation of xylose is found in both HS and CS linkage regions (Ueno et 
al., 2001).
Step Two: Heparosan Polymerization
HS biosynthesis involves the extension of a linear polysaccharide backbone followed by 
various modification steps.  The HS polysaccharide consists of up to 200 repeating 
disaccharide units of D-glucuronic acid 14 linked to N-acetylglucosamine 14.
HS copolymerase- Repeating units of glucuronic acid 14 linked to acetylated 
glucosamine are extended from the linker tetrasaccharide by the bifunctional HS 
copolymerase.  This enzyme is formed by peptides encoded by two genes, EXT1 and EXT2. 
EXT1 and 2 are type II membrane proteins that share 35% homology and possess 
glycosyltransferase activity (Lind et al., 1993; Wei et al., 2000).  The catalytic efficiency of 
the individual proteins are low, however their activity increases substantially when they form 
a hetero-oligomeric structure that localizes it to the Golgi (Kobayashi et al., 2000; 
McCormick et al., 2000).  
In vitro studies utilizing synthetic and affinity purified substrates containing the 
tetrasaccharide linkage region demonstrated that the EXT1/2 complex preferentially transfers 
GlcNAc and GlcUA to aglycons2 that possess hydrophobic moieties (Kim et al., 2003). This 
work also demonstrated that the GlcNAcT believed to initiate HS polymerization may be 
dispensable since EXT1/2 can utilize GlcUA1,3-Gal1,3Gal1,4Xyl1-O-Ser-Gly-Trp-Pro-
Asp-Gly as a substrate.  However the HS EXT1/2 could not distinguish between full length 
2
 Aglycon refers to an acceptor molecule of a glycosylation reaction.
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glypican, a known HS proteoglycan, and -thrombomodulin, a part-time3 proteoglycan.  
These findings may underscore the role of phosphorylated xylose and sulfonated galactose 
residues of the tetrasaccharide linkage region.  Mutations in either EXT 1 or 2 genes can lead 
to loss of HS production.  The hereditary bone disorder multiple exostoses linked to 
mutations in the EXT genes emphasizes the role these enzymes and HS in development (Zak
et al., 2002).  
Step Three: Polysaccharide Chain Modification
The functionality of the HS polysaccharide chain manifests through epimerization of D-
glucuronic acid to L-iduronic acid and various sulfation reactions.  The classes of enzymes 
that catalyze these reactions are C5 epimerase (EPI), the bifunctional N-deacetylase/N-
sulfotransferase (NDST), as well as the 2-O- 6-O-, and 3-O- sulfotransferases (2OST, 6OST, 
3OST respectively).  All of the sulfotransferases in the HS biosynthetic pathway utilize the 
sulfate donor 3’- phosphoadenosine 5’- phosphosulfate (PAPS) as a cofactor (Sugahara and 
Kitagawa, 2002).
N-Deacetylase N-Sulfotransferase- The N-deacetylase N-sulfotransferase is a bifunctional 
enzyme with two distinct catalytic activities.  One involves removal of the acetyl group of 
glucosamine while the other catalyzes the transfer of a sulfuryl group from the cofactor 
PAPS to an N-unsubstituted glucosamine unit.  The functional link between these two 
activities is obvious since most subsequent modification reactions require N-sulfonation.
3
 Part time proteglycan refers to those glycoproteins that have been isolated with and without GAG chains. 
Indeed some of these glycoproteins may only carry the GAG tetrasaccharide linkage region.  
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There are four distinct isoforms of the NDST gene (1 through 4) that possess unique tissue 
distribution patterns (Aikawa et al., 2001).  Isoforms 1 and 2 both display wide and 
overlapping tissue distribution while isoform 3 is restricted to adult mouse brain, heart, 
muscle, and kidney.  Isoform 4 is expressed in low levels of the brain and throughout 
embryonic development.  Esko and coworkers have reported translational control of the 
NDSTs through the structured 5’-untranslated region and internal ribosome entry sites
(Grobe and Esko, 2002).  These finding suggests that while mRNA of isoforms 1 and 2 are 
ubiquitous to most tissues, translational regulation of this class of enzymes may be one 
mechanism to control HS synthesis. 
The bifunctional activity of NDST has been demonstrated in several studies. Wei and 
Swiedler carried out a functional analysis of the cysteine residues of NDST (Wei and 
Swiedler, 1999). They concluded that the N-deacetylase activity of NDST prefers a reducing 
environment and is dependent on a cysteine residue at position 586 (rat liver NDST), while 
the N-sulfotransferase activity prefers a non reducing environment and is sensitive to most 
cysteine to alanine mutations of the full length protein.  Also, studies have shown that 
optimal N-deacetylase activity occurs at pH 6.5, while optimal N-sulfotransferase activity 
occurs at pH 7.5.  The N-sulfotransferase domain had been localized to the C-terminal 
domain.  Indeed a crystal structure of this domain has been attained as well as a molecular 
description of substrate binding and the catalytic mechanism (Kakuta et al., 1999).     
Figure 10 (A) shows that the overall shape of NST is roughly spherical with a large open 
hydrophilic cleft. Through molecular modeling and mutagenesis studies this open cleft was 
determined to be the substrate binding domain (Kakuta et al., 2003).  Through sequence 
alignment with other sulfotransferases the PAPS binding domain was determined to be 
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internal to the polysaccharide binding site, placing the sulfuryl group of PAPS in close 
proximity to its acceptor site at the N2 position of glucosamine.  The position of a glutamate 
residue relative to the bridging oxygen of the 5’ phosphoryl group and its close proximity to 
the N position of glucosamine in the modeled hexasaccharide (Figure 10B) make it a 
Figure 10. The heparin binding cleft of NST. Panel A shows the overall fold of the NST domain.  Panel B 
shows a HS hexasaccharide that has been modeled into the proposed HS binding cleft. Residue E642 is in close 
proximity to the N2 acceptor site and a modeled sulfuryl moiety of PAPS.
candidate to serve as a catalytic base. The glutamate residue should enhance the 
nucleophilicity of the amino group, promoting a SN2 type reaction mechanism.
The characterization of HS from mutant cell lines and knockout mice suggests that the 
type of functional unit at the N position (-Ac, -H, or -SO3H) of glucosamine dictates the 
amount of adjacent O-sulfo groups (Bame and Esko, 1989; Holmborn et al., 2004; Ledin et 
al., 2004).  Subsequently, it is sulfation patterning that determines the specificity of 
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interactions between HS and a target protein.  Some HS/protein interactions are found to 
occur in highly sulfated domains of HS while others can occur in more variably sulfated 
domains (Chen and Liu, 2005; Liu et al., 2002; Pye et al., 1998; Stringer et al., 2002).  This 
makes the NDST enzyme class a critical component in the biosynthetic pathway of 
multifunctional HS and heparin.  Indeed, NDST knockout mice reveal that NDST 1 is 
essential for development (Fan et al., 2000) while NDST2 is essential only for mast cell 
production (Forsberg et al., 1999; Lyon et al., 2000). 
Epimerase- Epimerase epimerizes the C5 carboxylate group of D-glucuronic acid 
converting it to L-iduronic acid.  The IdoA epimer is a flexible conformer of the uronic acid 
residue since it is in equilibrium between a chair and skew boat conformation.  This 
flexibility has been suggested to provide additional structural diversity in the HS 
polysaccharide for target protein binding.  In vitro, the epimerization reaction is reversible
(Hagner-Mcwhirter et al., 2000), however in cell culture, the reaction appears to be 
irreversible (Hagner-McWhirter et al., 2004).  Targeted disruption of the C5-epimerase 
results in an embryonic lethal phenotype in mice (Li et al., 2003).  The morphology of the 
HSepi-/- embryo is strikingly distinct from the wild type.  Some key differences include renal 
agenesis, immature lungs, and severe skeletal defects.  These embryos also express HS that 
carries substantially fewer sulfate groups than the wild type.  The HS EPI-/-  phenotype 
demonstrates the manifold and essential roles of structurally diverse HS in development.   
2-O-sulfotransferase- The 2-O-sulfotransferase catalyzes sulfo-transfer from PAPS to the 
2-O- position of an uronic acid unit (Kobayashi et al., 1996).  Characterization of HS isolated 
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from natural sources and in vitro sulfotransferase assays confirm that iduronic acid is the 
preferred acceptor over glucuronic acid (Rong et al., 2001).   Notably, 2OST is the only HS 
sulfotransferase that exists as a single isoform.  A gene trap mutation for 2OST results in 
renal agenesis and a neonatal lethal phenotype in mice (Bullock et al., 1998).  Esko and 
coworkers have demonstrated an interaction between 2OST and epimerase in vivo (Pinhal et 
al., 2001).  This finding highlights a potential mechanism whereby 2OST is able to locate its 
preferred substrate (IdoA) via a physical linkage with the enzyme that generates it.
6-O-Sulfotransferase- There are three members of the HS 6-O-sulfotransferase family.  
Isoform 1 appears to be strongly expressed in the liver, isoform 2 in brain, and isoform 3 
appears to be broadly expressed in most mouse tissue types (Habuchi et al., 2000). Two 
splice variants of the human 6OST2 have unique expression patterns (Habuchi et al., 2003). 
The original 6OST2 appears to be restricted to brain tissues while the second 6OST2 variant 
is expressed in additional tissues including ovary, kidney, and pancreas.   The role of the 
6OST1 gene in zebrafish has been studied using morpholino antisense oligonucleotides (Bink 
et al., 2003).  The loss of function phenotype displayed significantly reduced levels of 6-O-
sulfation, but not 2-O-sulfation in its heparan sulfate chains.  The 6OST knockdown showed 
developmental deficiencies in the white matter of axon bundles, high levels of myosinD 
expression, and severe muscle degeneration.  The substrate specificity of the 6OSTs has been 
characterized and does not appear to vary among the different isoforms (Smeds et al., 2003).  
It is notable that 6OST can act on both N-acetylated and N-sulfonated glucosamine residues.  
The enzyme prefers N-sulfonated glucosamine that is at the reducing end of IdoA over N-
sulfonated glucosamine at the reducing end of GlcA.   
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3-O-Sulfotransferase- The 3-O-sulfotransferases catalyzes sulfuryl transfer to the 3-
hydroxyl position of various glucosamine residues.  This modification is rare in heparan 
sulfate isolated from natural sources.  The first 3OST to be identified was initially purified 
from L-cell conditioned media and later cloned (Liu et al., 1996; Shworak et al., 1997).  It 
was determined that this enzyme makes the essential modification in the biosynthesis of 
anticoagulant heparin and heparan sulfate.  Subsequently, additional members of the 3OST 
family have been cloned and characterized (Shworak et al., 1999; Xia et al., 2002; Xu et al., 
2005).  The expression pattern for this family of enzymes is quite diverse.  The unique 
structures generated in AT- and gD- binding HS are largely due to the substrate selectivity of 
HS 3-O-sulfotransferases.  Studies have shown that different members of the 3OST family 
can transfer a sulfuryl group to the 3-OH position of several glucosamine residues modified 
to a different extent as shown in Figure 11 (Liu and Rosenberg, 2002). 
25
Figure 11.  Substrate specificities of 3-OSTs.  3OST1 transfers a sulfuryl group to the N-sulfo glucosamine 
(GlcNS±6S) residue that is linked to the nonsulfated glucuronic acid residue at the nonreducing end (GlcUA).  
3OST3 transfers a sulfuryl group to the N-unsubstituted glucosamine (GlcNH2±6S) residue that is linked to a 2-
O-sulfo iduronic acid (IdoUA2S) residue at the nonreducing end.  3OST5 transfers a sulfuryl group to the 
glucosamine (GlcNS±6S or GlcNH2±6S) residue that is linked to either nonsulfated or sulfated iduronic 
(IdoA±2S) and GlcUA residue.  It appears the 3OST3 and 3OST6 have similar substrate specificity.
Traditionally, this substrate selectivity has been described at the disaccharide level and 
correlates strongly with the biological function of the modified HS chain, as shown in Table 
II.  The disaccharide, GlcUA-AnMan3S±6S, observed in chemically depolymerized 3OST1 
and 5 modified HS is characteristic of anticoagulant HS while IdoUA2S-AnMan3S±6S, 
produced by isoforms 3OST2 through 6 is observed in gD-binding HS.
Table 2.  Summary of the products and biological functions of 3-OST- modified HS
Isoforms Characteristic disaccharides prepared from enzyme 
modified has
Biological functions of the enzyme 
modified HS
3OST1 GlcUA-AnMan3S±6Sb AT-binding HS
3OST2 GlcUA2S-AnMan3S and IdoUA2S-AnMan3S Unknownc
3OST3A IdoUA2S-AnMan3S±6S Entry receptor for HSV1d
3OST3B IdoUA2S-AnMan3S±6S Entry receptor for HSV1
3OST4e IdoUA2S-AnMan3S±6S Unknownc
3OST5 GlcUA-AnMan3S±6S, IdoUA-AnMan3S±6S and 
IdoUA2S-AnMan3S±6S
AT-binding HS and Entry receptor for 
HSV1
3OST6 IdoUA2S-AnMan3S±6S Entry receptor for HSV1
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a. The disaccharides were prepared by subjecting the enzyme-modified HS to the degradations of nitrous 
acid (AnMan represents 2,5-anhydromannitol; GlcUA and IdoA represent glucuronic and iduronic 
acid, respectively.).  AnMan is a product of nitrous acid degradation.
b. The 3-O-sulfo group is bolded and underlined to emphasize the modification by 3-OSTs.
c. A recent review by Shukla and Spear indicated that 3OST2 and 3OST4 generate entry receptors for 
HSV1 (Shukla and Spear, 2001).
d. HSV1 represents herpes simplex virus type 1.
e. The substrate specificity of 3OST4 was reported by Wu and colleagues (Wu et al., 2004).
Subsequent studies show that 3OST5 modified HS binds to antithrombin and to Herpes 
Simplex Virus glycoprotein D.  It has also been demonstrated that this enzyme generates a 
wide range of 3-O-sulfated disaccharides, including IdoUA2S-AnMan3S±6S, GlcUA-
AnMan3S±6S as well as IdoUA-AnMan3S±6S (Chen et al., 2003).  In an additional study on 
the substrate specificity of this enzyme, Mochizuki et al. (Mochizuki et al., 2003) isolated a 
unique tetrasulfated disaccharide, UA2S-GlcNS3S6S, from heparin modified by 3OST5.  
From these studies, 3OST5 appears to have a broad substrate specificity, which explains the 
fact that the products resulted from 3OST5 modification have multiple biological functions, 
including anticoagulant activity.  Indeed, using purified recombinant 3OST5 expressed in 
insect cells, we demonstrated that 3OST5 modified HS binds to antithrombin, and the 
percentage of AT-binding HS is comparable to that of the HS modified by purified 3OST1 
(Chen et al., 2003).  These results demonstrate that 3OST5 is capable of generating AT-
binding HS in vitro.  However, the role of 3OST5 in synthesizing antithrombin-binding HS 
in vivo and the activity of 3OST5 modified HS in the deactivation of AT-mediated factor Xa 
remains to be investigated.
The crystal structures of PAP in complex with 3OST1 (Edavettal et al., 2004) and a 
ternary complex of 3OST3, PAP, and the HS tetrasaccharide UA2S-GlcNS6S-IdoUA2S-
GlcNS6S (Moon et al., 2004) have been resolved.  In comparing the structure of the 
previously crystallized N-sulfotransferase (NST) (Kakuta et al., 1999) with 3OST1, it appears 
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that they share a similar overall structural fold (Figure 12).  However, in comparing the 
electrostatic potential diagram of the two enzymes as shown in Figure 10, it is evident that 
the proposed HS binding cleft of the 3OSTs contains more positively charged amino acid 
residues than that of NST (Edavettal et al., 2004). This observation fits well with our 
understanding of the differences in substrate preference between these two sulfotransferases 
since N-sulfonation of the glucosamine residue in HS is precursory to O-sulfation. The NST 
enzyme recognizes the unmodified structure, heparosan (-GlcUA-GlcNAc-)
n
(Kusche-
Gullberg and Kjellen, 2003), while the 3OSTs require more highly sulfated and negatively 
charged forms of HS (Liu et al., 1999).  It is proposed that the positively charged cleft in the 
3OSTs can provide more electrostatic contacts for the sulfated substrates of these enzymes.
Figure 12. A charged surface diagram of the proposed heparan binding cleft of the sulfotransferase 
domains of NST-1 (a) and 3-OST-1 (b). The global position of the cleft is marked with a green dashed line. 
Blue surfaces signify positive charge, whereas red surfaces signify negative charge. The double-sided dash 
arrows (in green) indicate the region where HS likely binds. This figure was created using Swiss PDB viewer.
The crystal structure of the 3OST3 ternary complex showed that the tetrasaccharide unit 
(shown in Figure 13) was bound in the positively charged cleft. As shown in Figure 14, the 
U4-G3 units make more contacts with the protein than the I2-G1 disaccharide unit.  The U4 
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unit, which is the uronic acid at the nonreducing end of the acceptor glucosamine unit, makes 
extensive contacts with 3OST3 and is predicted to play a role in substrate specificity.  Of 
particular interest, the residues Q255 and K368 make contacts with the 2-O-sulfo and C5 
carboxylate groups of U4 respectively. In Table 3 the 3OST3 point mutants Q255A and 
K369A show significantly reduced sulfotransferase activity.  Notably, these mutations in the 
3OST1 isoform do not impact
Figure 13.  The structure of the tetrasaccharide substrate.  The 3-O-sulfonation site is circled.  For clarity, 
U4 represents UA2S; G3 represents GlcNS6S linked to UA2S; I2 represents IdoUA2S; and G1 represents 
GlcNS6S at the reducing end.  
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Figure 14.  Stereo diagrams of the binding of 3OST3 and tetrasaccharide.  a) Stereo diagram of HS 
acceptor substrate binding cleft with tetrasaccharide (green) bound.  Residues that line the cleft are pictured.  
Displayed in blue is the simulated annealing Fo-Fc omit electron density map contoured at 2.  b) Stereo 
diagram displaying the interactions between 3OST3 and U4-G3 units.  The O3 oxygen of G3 unit is labeled. c) 
Stereo diagram of the interactions between 3OST3 and I2-G1 units.  A metal ion modeled as a sodium ion is 
colored cyan, as are interactions between the metal and the coordinating atoms.  Possible hydrogen bonds 
between the protein and tetrasaccharide are displayed as black dashed lines.  These figures were created using 
Molscript and Raster3d (Kraulis, 1991; Merritt and Bacon, 1997).
enzymatic activity as critically, suggesting that these residues may affect HS binding rather
than sulfo-transfer (Moon et al., 2004).  One potential explanation for these differences is 
that these residues are not as significant in substrate recognition of 3OST1.  It should be 
noted that the commonly characterized HS disaccharide structure modified by 3OST1 is 
GlcUA-GlcNS3S6S.   
a.
b.
c.
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Table 3. Analysis of the sulfotransferase activity of selected 3OST1 and 3OST3 mutants.
3OST1 constructa % Activityb 3OST3 constructa % Activityb
R67E 1.1 K161A 0.4
R72E 0 R166E 0.2
K123A 0.2 K215A 0.1
Q163 34 Q255A 0.4
K274 17.4 K369A 0.1
a. The mutants were prepared using a site-directed mutagenesis kit from Invitrogen and purified.
b. The activity of 3OST3 was assayed by incubating the purified mutant proteins with HS and [35S]PAPS, and 
the resultant [35S]HS was quantified by DEAE chromatography.  100% activity represents the transfer of 18 
pmoles of sulfate/µg of protein under the standard assay condition.
The ternary complex provides a great deal of information about contacts between the 
enzyme and those HS residues adjacent to the acceptor glucosamine unit.  Many questions 
remain about the interactions that extend beyond this site. In addition, conformational 
changes observed in the 3OSTs upon heparan binding suggest a potential for allosteric 
effects that can impact enzyme function.
Physiologic and Pathophysiologic Roles of HS
Cardiovasaular biology- HS plays a critical role in controlling the blood coagulation 
process (Conrad, 1998).  Heparin, a HS analogue, is the most commonly used anticoagulant 
drug due to its functions as a cofactor in the AT-mediated inhibition of factor Xa and 
thrombin.  The 3OST isoform 1 has been shown to make the essential modification of high 
affinity AT-binding HS (Liu et al., 1996).  A recent report of a murine 3OST1 knockout 
model has raised some questions about the role of this enzyme in hemostasis
(HajMohammadi et al., 2003). They observed that levels of AT-binding HS in 3OST1-/- 
mice were not completely eliminated, nor did these animals possess a procoagulant 
phenotype.  It was suggested that in these models, additional anticoagulant factors 
compensated for the loss of AT-binding HS generated by 3OST1.  As a follow up to this 
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work they demonstrated that in epithelial cells of the glomerulus of the 3OST1-/- mouse,
additional 3OSTs can generate anticoagulant HS from a limiting precursor pool of HS
(Girardin et al., 2005).  These results suggest that expression of one isoform of the 3OSTs 
may be insufficient to observe a procoagulant phenotype. In order to completely delineate the 
role of anticoagulant HS in the blood coagulation cascade it is essential to generate a model 
organism that is completely devoid of 3-O-sulfated HS polysaccharides.  The biosynthesis of 
AT-binding HS is believed to be highly regulated, which is supported by the fact that only 1 
to 10% of total HS isolated from the cells bind to AT.  
Heparanase in cancer- Heparanase is a heterodimeric endoglycosidase that specifically 
cleaves the polysaccharide chain of HSPGs.  Heparanase is a glycosylated molecule that is 
secreted into the extracellular matrix by a variety of normal cells including platelets, 
neutrophils, and activated lymphocytes.  Overwhelming genetic and biochemical evidence 
implicates heparanase in cancer progression (Baraz et al., 2006; Hulett et al., 1999; Joyce et 
al., 2005; Roderick M. Quiros, 2006; Simizu et al., 2004; Vlodavsky et al., 1999).  The 
heparanase gene is overexpressed in malignant cancer cells including carcinoma (Kim et al., 
2002), melanoma (Kelly et al., 2003; Motowo Nakajima, 1988), and breast cancer 
(Maxhimer et al., 2002).  A significant increase in heparanase activity in the serum of cancer 
patients is often associated with a poor prognosis (Roderick M. Quiros, 2006).  A study that 
utilized a HS mimetic, PI-884, in vivo demonstrated that this molecule can decrease tumor 
cell proliferation, increase apoptosis, and decrease angiogenesis (Joyce et al., 2005).  These 
effects were due in part to a reduction in the association of VEGF, a HS binding protein, with 
its cognate receptor.  The authors suggest that the increased metastatic potential of tumors
4
 PI-88 is a sulfated phosphomannopentose molecule isolated from yeast and chemically sulfonated. 
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that express heparanase may, in part, be the result of improved growth factor mobilization 
within the microenvironment.
Microbial attachment and cellular entry- A variety of microbes including bacteria, viruses, 
and parasites utilize HSPGs to make initial attachment to host epithelia.  After attachment,
the microbe can colonize the host or be internalized by a variety of entry mechanisms. The 
role of cell surface HS has been validated in these processes by the observed loss of 
colonization through the administration of exogenous HS and heparin, and through the 
chemical or genetic ablation of cell surface HSPGs (Alvarez-Dominguez et al., 1997; 
Taraktchoglou et al., 2001; Tonnaer et al., 2006).   
Recent studies have also demonstrated that soluble forms of HSPGs and heparin can serve 
as virulence factors for gram negative bacteria (Park et al., 2004; Park et al., 2001; Park et 
al., 2000a).  Pseudomonas aeruginosa has been shown to secrete a soluble factor LasA that 
can promote the release of the cell surface HSPG syndecan 1 from lung epithelial cells. In the 
presence of soluble HSPGs, exogenous HS, and heparin, the ability of the microbe to 
colonize and invade host tissues is substantially enhanced. The mechanism for this enhanced 
virulence is unclear but studies have suggested that soluble HSPGs can serve to alter the host 
immune response. For example HS can bind to circulating antimicrobial peptides.  
Additionally, HSPGs are important in the chemotaxis of leukocytes (Li et al., 2002; Wang et 
al., 2005).  Alterations in the immune response can serve to create an environment that is 
amenable to microbial infection. 
A variety of microbes promote interaction with its host by binding extracellular matrix 
proteins.  Pathogens also use host matrix components to evade the immune response.  Studies 
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have shown that Neisseria gonorrhoeae and other pathogenic bacteria can bind vitronectin 
and fibronectin via heparin and HS (Duensing and Putten, 1998; Duensing et al., 1999; 
Gómez-Duarte et al., 1997). 
Chemoenzymatic Synthesis of Heparin and HS Analogues
With the multitude of biological functions of heparin and HS, it is of great interest to 
expand current chemical methods to synthesize structurally defined oligosaccharides.  Access 
to a variety of well defined heparin analogues will aid in the development of structure 
activity relationships for this therapeutically relevant molecule.  The monumental synthesis 
of the AT activating pentasaccharide by Petitou represents the beneficial role of producing 
specific heparin structures to examine their role in a pathophysiologic context (Petitou et al., 
1986).  The low yield (~0.4%) coupled with the approximately 80 step synthesis of the 
pentasaccharide also emphasizes the need to develop strategies to complement the de novo
synthesis of heparin oligosaccharides.  Solid phase methodologies along with the 
development of advanced protection group chemistry may aid in realization of more feasible 
routes to heparin production (Noti and Seeberger, 2005).  Another more recent advancement 
in this area is the use of enzymatic and chemoenzymatic methods to generate heparin and HS 
analogues (Chapman et al., 2004).
Enzymatic and chemoenzymatic synthesis of heparin- For over 70 years, various forms of 
heparin have been used in the clinic to treat thrombotic episodes and as prophylaxis during 
invasive surgery (Linhardt, 2003).  The HIT side effects associated with heparin treatment 
have been reduced with the use of low molecular weight heparins (LMWHs) (Sundaram et 
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al., 2003). However, since heparin is a natural product, there is a potential for the presence 
of animal-borne pathogens in these preparations.  Also, if the therapeutic potential of heparin 
is to be extended beyond anticoagulation, the heterogeneity of heparin should be reduced
(Lever and Page, 2002).  Recently it has been demonstrated that challenges associated with 
the de novo chemical synthesis of heparin may be overcome with the use of HS biosynthetic 
enzymes. These catalysts provide proper regio-selective sulfonation and can be carried out in 
a combined or stepwise manner. Rosenberg and colleagues have pioneered this approach in 
three papers published in 2003.  In their first effort the group synthesized low microgram 
quantities of anticoagulant heparin termed “Mitrin” with measured activity against factor Xa 
(Kuberan et al., 2003a). They reported the expression of NDST2, epimerase, 6OST2, and 
3OST1 using a baculovirus expression system. Using the capsular polysaccharide from the 
K5 strain of E. coli, a rapid two step synthetic route was carried out.  NDST and epimerase 
reactions were coupled in the first step while 6OST2 and 3OST1 mediated reactions were 
carried out in the second.  Surprisingly, the group reported 70% of the dissacharide units 
contained IdoA and nearly 50% of the disaccharide units contained 3-O-sulfo glucosamine. 
Previous reports of epimerization in the absence of 2-O-sulfonation suggested that N-
sulfonated HS could contain 50% IdoA acid since the epimerization is a reversible reaction. 
Additionally 3-O-sulfation is a rare constituent of HS and heparin (between 0.5-10% for HS 
and approximately 30% for heparin), and the paucity of this modification was believed to be 
the result of a restricted enzyme substrate specificity.  The authors also demonstrated that the 
Mitrin preparation has 4-5 times the anti-factorXa activity of heparin, when using an in vitro
spectrometric assay.  Importantly, 2-O-sulfation was excluded from the preparation because 
this modification is important in PF4 binding heparin.  The absence of 2-O-sulfation could 
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minimize HIT if Mitrin is applied in a clinical setting.  One challenge in Mitrin synthesis is 
the use of PAPS in the reaction.  PAPS is an expensive molecule to produce and is not very 
stable at pH  7.  Also the by-product of PAPS is PAP and this molecule can inhibit the 
sulfotransferase reactions with an IC50 of approximately 100 µM.  
In a second report Rosenberg and colleagues utilized a chemoenzymatic strategy to 
synthesize anticoagulant heparin (Kuberan et al., 2003b).  In this effort the authors devised a 
stepwise synthetic route that involved the base catalyzed deacteylation and regio-selective N-
sulfonation with the reagent trimethylamine sulfur trioxide.  This first step was followed by 
subsequent enzymatic reactions outlined in Figure 15. In this approach the degree of 
epimerization was increased to 85% while that of 3-O-sulfation was reduced 5-17 fold based 
the number of 3-O-sulfated disaccharides.  The increase in the degree of epimerization could 
be due to the increase in N-sulfo glucosamine which is a prerequisite for the epimerase-
mediated conversion of glucuronic acid to iduronic acid.  A potential explanation for the 
reduction in 3-O-sulfation is the increased percentage of IdoA acid.  The characteristic 
disaccharide unit in 3OST1 modified heparin is GlcA-GlcNS3S±6S.  The increase in 
epimerization would lead to a decreased availability of the preferred substrate for 3OST1.
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Figure 15. The synthetic route to anticoagulant heparan sulfate. Chemoenzymatic synthesis of heparan 
sulfate was carried out in six steps.  Chemical deacetylation and N-sulfonation of K5P resulted in the N-sulfo 
K5 precursor for subsequent enzymatic reactions.  Each of the enzymatic reactions were carried out in a 
stepwise manner.  
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In their final effort, Rosenberg and colleagues utilized an enzymatic approach to 
synthesize the AT binding pentasaccharide (Kuberan et al., 2003c) through the synthetic 
route depicted in Figure 16.  In order to generate the polysaccharide they utilized heparitinase 
I to degrade the non N-sulfonated domain of NDST modified K5 polysaccharide.  This 
enzyme proceeds through an elimination type mechanism to generate 4,5 unsaturated uronic 
acid residues (Hovingh and Linker, 1970; Lohse and Linhardt, 1992).  The hexasaccharide 
was then used as a substrate for the subsequent sulfotransferase and epimerase reactions.  In 
their synthetic route 2OST and epimerase reactions were coupled as well as 6OST1 and 
6OST2 reactions.  Hexasaccharides containing the unsaturated uronic acid were purified by 
size exclusion and then cleaved to a pentasaccharide by the hydrolase 4,5 glucuronidase.  In 
the final step the pentasaccharide was modified with 3OST1 and radiolabeled PAP34S in 
order to purify it from nonreacted material and to perform a gel shift assay.
Another unique chemoenzymatic approach for anticoagulant “neoheparin” has recently 
been published by Lindahl and coworkers (Lindahl et al., 2005) .  The overall approach to 
attain anticoagulant heparin was complete sulfonation of K5 polysaccharide, partial 
epimerization, followed by graded desulfation via solvolysis.  The first step in the strategy 
was to perform regio-selective N-sulfonation on capsular K5 polysaccharide, followed by 
epimerization with epimerase.  In the next steps, the author use a per-O-sulfonation in which 
all of the hydroxyl groups on the polysaccharide are sulfonated, followed by graded 
solvolytic desulfonation to selectively remove some of the O -sulfuryl groups.  In the final 
step of the synthesis, controlled cleavage of the polysaccharide was carried out with nitrous 
acid.  Upon structural analysis of the final product, approximately 46% of glucosamine was 
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3-O-sulfated.  The authors reported gram scale preparation with activity against factor Xa 
and
Figure 16. Enzymatic synthesis of the HS derived AT binding pentasaccharide. The K5P polysaccharide 
was partially N-sulfonated with NDST isoform 2 followed by partial enzymatic degradation by heparitinase I 
which preferentially cleaves at the glycosidic linkage between glucuronic acid and N-acetyl glucosamine. 
Hexasaccharide fragments were isolated and subjected to additional modifications. Unlike their previous effort, 
epimerization and 2-O-sulfonation reactions were coupled together.  To access the pentasaccharide, the 
hydrolytic 4,5glycuronidase was used to remove unsaturated uronic acid at the nonreducing end. The synthesis 
was completed with the 3OST1 modification of the pentasaccharide.   
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thrombin that is similar to heparin.  The major limitation in this work is the presence of 
unnatural sulfuryl groups in the polysaccharide, specifically at the C3 position of glucuronic 
and iduronic acid.  These moieties can have a negative impact on the anticoagulant activity of 
the neoheparin and were reported in <5% (IdoA) and 46% (GlcA) abundance.
In 2005 Chen et al. reported an enzymatic approach to the synthesis of heparin with 
anticoagulant, gD-binding, and FGF binding (Chen et al., 2005) activities. The advances of 
this effort were the milligram scale preparation that only requires two or three steps.  In this 
approach, heparin was selectively de-O-sulfonated, followed by redesign of the 
polysaccharide with 2-O-, 6-O-, and/or 3-O-sulfotransferases as shown in Figure 17A .  A 
major advantage to this approach is the use of a PAPS regeneration system (Figure 17B) 
developed by Wong and colleagues.  In this system the rat arylsulfotransferase IV (AST IV) 
and high concentrations (5-10 millimolar) of the small molecule p-nitro phenol sulfate 
(PNPS) is used to convert PAP to PAPS.  The advantages of this system are threefold: 1) 
Only catalytic amounts of PAP (~40µM) are required, thus allowing reaction scale up while 
limiting the potential for PAP mediated enzyme inhibition, 2) AST IV can be prepared easily 
and in large quantities (40-50 milligrams per liter in a bacterial expression system), and 3) 
PAP and PNPS are substantially less expensive and more stable reagents than PAPS. 
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Figure 17. A schematic of the synthesis of sulfated polysaccharides and the PAPS regeneration system.
The stepwise enzymatic synthesis of sulfated polysaccharides using HS sulfotransferases is shown in panel A. 
Compound 1 was prepared by solvolysis using dimethyl sulfoxide/methanol mixture (9:1, v/v) at 80 °C for 24 h.  
Compounds 4a and 4b were prepared by inverting the order of sulfation steps. 4a was prepared by incubating 
compound 1 with 2OST followed by 6OST, whereas 4b was prepared by incubating compound 1 with 6OST 
followed by 2OST. Panel B depicts the reaction cycle catalyzed by arylsulfotransferase IV (AST IV) to generate 
PAPS. R represents -H or -SO3H. Figure was adapted from (Chen et al., 2005)
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Statement of Problem
From the structural heterogeneity and manifold functions of HS and heparin it is readily 
evident that the biosynthetic pathway of these biomolecules is complex.  In order to 
understand how this complexity arises, it is essential that the components of this pathway are 
explored.  In addition, expansion of the therapeutic potential of HS and heparin depends on 
the development of efficient strategies to synthesize well defined oligosaccharides of varying 
length.  The chemoenzymatic synthesis of heparin analogues is a promising method to attain 
biologically relevant heparin structures in sufficient quantities.  This work focuses on two 
major challenges in the pursuit of heparin synthesis. Specifically, the further elucidation of 
two isoforms of the essential biosynthetic enzymes NDST and 3OST as well as the 
development of a chemoenzymatic approach to synthesizing anticoagulant heparin analogues 
will be addressed.  
Heparan sulfate 3OST5 is a unique member of the 3OST family based on its broad 
substrate specificity in vitro.   Previous work involved the molecular cloning, expression and 
purification of this novel family member. Additional work involved the detailed 
characterization of the HS structures generated by this enzyme.  Chapter III of this text 
describes the functional analysis of 3OST5 involvement in the biosynthetic pathway of 
anticoagulant HS. A stable cell line that expresses 3OST5 was generated and characterized 
for its ability to generate AT activating HS.  This cell line has proven useful in studying 
additional functional roles of 3-O-sulfated HS and should prove useful for future efforts to 
delineate the roles of 3OST5 modified HS.  
    The HS NDST family of sulfotransferases is essential in the production of biologically 
active HS structures.  The N-sulfotransferase domain of this enzyme has been studied at 
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some length.  Localization of the dually important N-deacetylase activity in this bi-functional 
enzyme has remained elusive. Chapter IV outlines efforts towards the expression and 
characterization the N-terminal domain of NDST and proves that this domain possess N-
deacetylase activity.  This preliminary work should lead to a more detailed understanding of 
the mechanisms of NDST action, and initiate efforts to use this enzyme in the synthesis of 
HS and heparin analogues.   
Heparin and HS isolated from natural sources are heterogeneous in nature. Chemical 
synthesis of heparin is not feasible beyond the oligosaccharide level, yet much of the 
biological activity is dependent on polysaccharide length. The development of a 
chemoenzymatic approach to producing heparin should significantly reduces synthetic 
complexity (no protection/deprotection steps) while affording proper regio-selective 
sulfonation of the polysaccharide. Chapter V presents a chemoenzymatic synthesis of 
anticoagulant heparin analogues that will serve as the basis for the milligram scale 
preparation for additional studies.  The relative ease of this method should allow its extension 
into the development of additional types of HS and heparin based therapeutics.
CHAPTER II. METHODS
General Procedures
Mammalian cell culture- Maintenance of CHO cells was performed according to 
established protocol.  Cells were grown in a T75 flask with F12 media (Gibco) supplemented 
with 10% Fetal Bovine Serum (FBS, JRH Bioscience) and the appropriate antibiotics 
Penicillin/Streptomycin or Geneticin 418 (for selection of stable expression cell lines).  Once 
cells reached 85-90% confluence, the cells were passaged using a standard protocol.  Briefly, 
cells were washed three times with 1× Phosphate Buffered Saline (Gibco), and detached from 
the flask with 2 mL of buffered trypsin, EDTA (Gibco) at 37 °C.  Once detached, the cells 
were diluted to 10 mL with F12 media and the concentration (cells/mL) was determined 
using a hemocytometer under microscope.  Cells were seeded into new flasks at 
approximately 105 cells per flask.  Cells were considered metabolically active after at least 
three rounds of passage.
For long term storage, cells were passaged as described above and then centrifuged at 
1000×g for ten minutes.  The cells were then resuspended in FBS with 10% dimethyl 
sulfoxide5 and frozen slowly at -80 °C by placing them in a double insulated box.
Preparation of chemically competent origamiB cells expressing groES/EL- The groES/EL 
5
 Cells concentration was typically 107 cells/mL
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chaperone (Takara Mirus Bio, Japan) system was employed to improve protein expression 
and solubility. OrigamiB cells (Novagen) were transformed with the pG-KJE8 construct that 
carries groEL and groES. Briefly, 10ng of plasmid was mixed with 100 µL of the bacterial 
cell suspension and incubated on ice in a 1.5 mL eppendorf tube for 30 minutes with 
intermittent mixing by tapping the tube. The cells were heat shocked at 42 °C for 45 seconds 
and then placed directly back on ice for two minutes.  Next, 0.9 mL of pre-warmed SOC 
media was added to the tube and the shaken at 250 rpm for one hour. Varying amounts (50-
500 µL) of the transformation reaction was plated on agar plates containing 20 µg/mL 
chloramphenicol.  The plates were incubated at 37 °C for 12-15 hours.  A single colony was 
selected and amplified in 2mL of Luria Broth (LB) media overnight by shaking at 250 rpm at 
37 °C.  To prepare chemically competent cells, the next day 100 mL LB media was 
inoculated with 1 mL of the overnight cell culture and shaken vigorously at 37 °C until the 
OD600 reached ~0.25-0.3.  The culture was chilled on ice for 15 minutes, and then centrifuged 
for 10 minutes at 3300×g and 4 °C.  The media was decanted and the cell pellet was 
resuspended in 30-40 mL of ice cold 0.1 M calcium chloride.  The cell suspension was kept 
on ice for 30 minutes and centrifuged again.  The cell pellet was resuspended again in 6 mL 
of 0.1 M calcium chloride and 15% glycerol.  The suspension was aliquoted at 200 µL and 
frozen in a dry ice and ethanol bath before storage at -80 °C.  The cells were designated 
oriBgroEL/ES. 
Agarose gel electrophoresis- PCR products and DNA plasmid construct quality were 
assessed by agarose gel electrophoresis.  Briefly, a 1% agarose solution was made by 
microwaving 0.4 g agarose with 40 mL 10 mM Tris-acetate 1 mM EDTA (TAE) buffer.  
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Once the solution cooled to ~70 °C, 1 µL of 5 mg/mL solution of ethidum bromide was 
added and the agarose was poured into a standard gel casting box with a well comb.  After 
the gel set 1x TAE buffer was added to the gel box and samples were diluted 2 fold with 
loading buffer (50% glycerol, 0.0125% bromophenol blue) and added to separate wells.  The 
gel was run at 120 volts and analyzed under UV light. 
Concanavalin A(ConA) sepharose aging-  In a column format, ConA Sepharose (Sigma-
Aldrich) was washed with 2 column volumes of AT binding buffer that contains 10 mM Tris-
HCl (pH 7.5), 150 mM sodium chloride, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 µM 
dextran sulfate, 0.02 % sodium azide and 0.0004 % Triton X-100.  The ConA Sepharose was 
then transferred to a 50 mL centrifuge tube and incubated at room temperature in the AT 
binding buffer for one hour with end over end rocking.  The buffer was eluted and replaced 
with 1% FBS in AT binding buffer and incubated under previously stated conditions. The 
beads were then eluted and washed with 10 mM Tris-HCl (pH 7.5), 1000 mM sodium 
chloride, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 µM dextran sulfate, 0.02 % sodium azide
and 0.0004 % Triton X-100.  The beads were re-equilibrated with the AT binding buffer and 
incubated with 1 mg/mL heparin at a final volume of 40 mL as stated above.  The beads were 
again washed with a high salt solution and stored at 4 °C in the AT binding buffer. 
Polysaccharide Preparation
Heparosan isolation- K5 E. coli strain was grown in LB media at 37oC overnight.  If [3H] 
labeled heparosan was to be prepared, D-[3H]glucose was added at a concentration of 2 
µCi/mL once the culture reached an OD600 of 0.2.  The overnight culture was centrifuged for 
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10 min at 6000 × g.  The supernatant was collected and diluted in equal volume of 20 mM 
sodium acetate buffer, pH 4.   The diluent was then filtered through 0.45 µm filter and 
applied to a 10 mL diethylaminoethyl sephacel (DEAE, Sigma) column that was pre-
equilibrated with 100 ml of 20 mM sodium acetate, 50 mM sodium chloride, pH 4.  The 
column was washed with 20 ml of the same buffer and eluted with 100 ml of 20 mM sodium 
acetate, 1000 mM sodium chloride, pH 4.  Three hundred milliliters of absolute ethanol was 
added to the eluted material and chilled at -20 oC for at least 4 hours.  Next, the mixture was 
centrifuged at 6000 × g for 30 minutes.  The supernatant was decanted and the pellet was re-
solubilized in 3 mL of 1M NaCl.  The remaining protein was removed by phenol/chloroform 
extraction.  One additional ethanol precipitation was performed and the resultant heparosan 
was further purified by gel permeation chromatography on a TSK-GEL G2500PWXL 
column (7.8mm × 30 cm, TOSOH BIOSEP) with a mobile phase of 100mM ammonium 
bicarbonate at a flow rate of 0.5 mL/min.  The fractions containing [3H] radioactivity were 
collected and dried.  The pellet was resuspended in water.  The amount of heparosan and 
specific [3H]activity of 3H-labeled heparosan were determined using the reverse phase ion-
pairing (RPIP)-HPLC disaccharide analysis described below.  
Preparation of [35S]HS- Wild-type CHO and 3OST5/CHO (preparation described below) 
were grown to 90% confluence in F12 media containing 10% FBS and 100 Units/mil 
Penicillin/Streptomycin or 1 mg/ml G418 respectively.  Cells were grown in the growth 
media containing 1 mCi/ml of sodium [35S]sulfate (ICN) for 10 h. [35S]HSPGs were 
harvested and purified on a DEAE column and subjected to -elimination under alkaline 
conditions followed by phenol extraction to remove polypeptides. [35S]HS was then isolated 
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by ethanol precipitation.  The estimated specific 35S-radioactivity of the [35S]HS was 4 x 107
cpm/µg.  We observed that the yield of [35S]HS from 3OST5/CHO cells was about 50% of 
that from wild type CHO cells.
Preparation of [3H, 35S] HS- Cells were grown in low glucose media as described by 
Invitrogen (www.invitrogen.com), 10% dialyzed FBS, 0.1 mCi/mL sodium [ 35S] sulfate and 
0.12 mCi/mL [3H]glucosamine hydrochloride (ICN) overnight.  The [3H,35S]HS was purified 
as described above.
[35S]PAPS Preparation
[35S]PAPS was prepared using adenosine 5’ triphosphate (ATP), [35S]Na2SO4, and dialyzed 
yeast extract.  The reaction was assembled in a final volume of 5 ml of 120 mM Tris-HCl 
(pH = 8.5), 36 mM MgCl2, 16 mM ATP (Sigma), 5 mg/ml dialyzed yeast extract (Sigma) 
and 0.4 to 2 mCi/ml [35S]Na2SO4 (carrier-free, ICN).  This reaction was incubated at 37 ºC 
for 1 hour.  After 1 hour, the reaction was terminated by boiling the solution for 2 minutes.  
The solution was centrifuged at 10,000 g for 10 minutes to remove any insoluble material 
and the supernatant was reserved.
The [35S]PAPS was purified from the reaction mixture using anion-exchange 
chromatography.  A 2 mL DEAE column was equilibrated with 10 mL of 10 mM 
triethylammonium bicarbonate buffer (TEA buffer, pH = 8.1), and then the supernatant was 
applied.  The column was washed with 10 mL of 200 mM TEA buffer and then eluted with 4 
mL 400 mM TEA buffer.  The eluent was dried and stored at –80 ºC.  
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Purity and specific activity were determined using a silica based amino-bound anion 
exchange HPLC column (0.46 x 24 cm, Waters).  The [35S]PAPS was eluted by a gradient of 
1 M potassium phosphate monobasic (30% to 100% in 60 min. at 0.5 ml/min.) and detected 
using an on-line radioactive detector and by UV absorbance.  [35S]PAPS absorbs UV light at 
 = 266 nM.  The UV and radioactive peaks for [35S]PAPS will overlap (elutes at 
approximately 38 minutes) and allows for purity determination (the ratio of [35S] found in the 
[35S]PAPS peak to all other [35S] peaks). 
Protein Expression and Purification
Preparation of NDase expression plasmid- The N-terminal domain of human NDST2 
(A66-P604) was cloned into a PET21b vector (Novagen) using the BamH1 and Hind III sites 
to generate NDase-(His)6 fusion protein.  The full length cDNA of human NDST-2 was a gift 
from Dr. Rosenberg (Massachusetts Institute of Technology).  The coding region of the 
expression plasmid was sequenced to confirm the reading frame and the absence of 
deleterious mutations (University of North Carolina DNA sequencing facility).
Expression of NDase was achieved in oriBgroEL/ES.  The bacteria were grown in LB 
medium supplemented with 12.5 µg/mL tetracycline, 15 µg/mL kanamycin, 35 µg/mL
chloramphenicol, and 50 µg/mL carbenicillin at 37°C.  When the OD600 reached 0.6–0.8, 
Isopropyl--D-thiogalactopyranoside (IPTG) and L-arabinose6 was added to a final 
concentration of 0.1mM and 1mg/ml, respectively.  Cells were pelleted at 7000×g for ten 
minutes and resuspended in buffer containing 25 mM Tris, 500 mM NaCl, 10mM imidazole, 
pH 7.5. The suspension was sonicated at duty cycle 50% and output control 7.  The protein 
6 L-Arabinose is used to induce expression of the groEL/ES construct.
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was purified by NTA-agarose column (Qiagen) following the protocol provided by the 
manufacturer.  Protein yield and concentration were determined by SDS-PAGE and A280 nm 
absorbance.  Typically, 5-7 mg of NDase protein was purified from a 1L culture and purity 
was ~50%.
Expression of N-sulfotransferase (NST)- The NST expression plasmid was obtained from 
Dr. Negishi (National Institute of Environmental Health Sciences). Glutathione transferase-
NST fusion was expressed in BL 21 cells and purified as described by Kakuta and colleagues 
(Kakuta et al., 1999).     
    Preparation of C5-epimerase bacterial expression plasmid and protein expression- The 
catalytic domain of human C5-epimerase (E53-N609) was cloned into pMAL-c2X vector 
(New England Biolabs) using the BamH1 and HindIII sites to generate a maltose-binding 
protein (MBP)-epimerase fusion protein. The full length cDNA of C5-epimerase was a gift 
from Dr. Rosenberg (Massachusetts Institute of Technology). Expression of C5-epimerase 
was achieved in oriBgroEL/ES.  The bacteria were grown in LB medium supplemented with 
2 mg/mL glucose, 12.5 µg/mL tetracycline, 15 µg/mL kanamycin, 35 µg/mL 
chloramphenicol, and 50 µg/mL carbenicillin at 37 °C. When the OD 600 nm reached 0.6–
0.8, IPTG and L-arabinose were added to a final concentration of 0.1 mM and 1 mg/mL, 
respectively. The protein was purified following the protocol provided by the manufacturer. 
The purified protein migrated at 97 kDa on SDS–PAGE with the purity greater than 60%.
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Preparation of 2OST and 6OST1 bacterial expression plasmid and protein expression-
The catalytic domain of 2OST of Chinese hamster ovary (Arg51–Asn356) was cloned into 
the pET21 vector (Novagen) using the Nde I and Hind III sites to generate a C-terminal His6
tagged fusion protein. The full-length cDNA of 2OST was a gift from Dr. Rosenberg 
(Massachusetts Institute of Technology, Cambridge, MA).  The catalytic domain of mouse 
6OST1 (His53–Trp401) was cloned into the pMAL-c2X vector (New England BioLabs) 
using the BamHI and HindIII sites to generate maltose-binding protein fusion protein. The 
full-length cDNA of 6OST1 was a gift from Dr. Kimata (Aichi University, Japan), 
respectively.   The expression of 2OST and 6OST1 was achieved in oriBgroEL/ES and Rosetta-
gami B (DE3) cells (Novagen), respectively, using a standard procedure.  Briefly, cells 
containing the plasmid expressing 6OST1 were grown in LB medium supplemented with 2 
mg/mL glucose7, 15 µg/mL tetracycline, 15 µg/mL kanamycin, 35 µg/mL chloramphenicol, 
and 50 µg/mL carbenicillin at 37oC.  When the OD600 reached 0.6-0.8, the temperature was 
reduced to 22C and IPTG was added at a concentration of 0.1 mM (L-arabinose was added to 
2OST at a final concentration of 1 mg/mL). 2OST expressing cells were grown in a similar 
fashion with the exception of the addition of glucose.  The bacteria were harvested, and the 
proteins were purified by affinity chromatography following a protocol from manufacturer 
(Qiagen and New England Biolabs).  The purified proteins migrated on 12% SDS-PAGE
with the purity greater than 90 % (2OSTHis) and 60% (6OST1MBP).  The yield for 2OST 
was approximately 20 mg/liter and 6OST1 was 50 mg/liter
7
 Glucose is used in the growth media to reduce expression of amylase. Amylase can degrade the amylose 
affinity column (New England Biolabs) used in the subsequent purification step. 
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Preparation of 3OST1 bacterial expression plasmid and protein expression- The cDNA 
fragment encoding the catalytic domain of 3OST1 (Gly48-His311) was amplified from 
3OST1 pcDNA3 containing an NdeI site and EcoRI site and inserted into the pET28a vector 
(Novagen) using the NdeI and EcoRI restriction sites to produce an N-terminal His6 tagged
protein. The resultant plasmid (3OST1) was sequenced to confirm the reading frame and the 
lack of mutations within the coding region (University of North Carolina, DNA sequencing
core facility). The plasmid, 3OST1, was transformed into BL21 (DE3)RIL cells (Stratagene) 
for the expression of 3OST1. Cells containing the 3OST1 were grown in 1 liter of LB media 
with 50 µg/ml kanamycin at 37 °C. When the A600 reached 0.6-0.8, the temperature was 
lowered to 22 °C for 30 min. IPTG was then added to a final concentration of 100 µM, and 
the cells were allowed to shake overnight. Cells were pelleted and resuspended in 120 ml of 
sonication buffer, 25 mM Tris, pH 7.5, 500 mM NaCl, and 10 mM imidazole. Cells were 
disrupted by sonication, and 3OST1 was purified as described above. Enzyme yield was 
approximately 20-25 mg/liter
Preparation of AST IV bacterial expression plasmid and protein expression- N-terminal 
(His)6 tagged AST-IV was expressed in E. coli and purified as described by Burkat and 
colleagues (Burkart et al., 2000) at a yield  50 mg/liter of bacterial culture.  The full length 
cDNA of rabbit AST-IV was a generous gift of Dr. Michael Duffel (University of Iowa) 
(Sheng et al., 2004).  
Enzymatic Activity Assay
N-deacetylation of heparosan by NDase- Purified heparosan was added to buffer 
containing 50mM MES pH 6.5, 0.5% Triton X 100, and 10 mM MnCl2.  Typically 5-200 µg 
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of total protein was added to the reaction and allowed to incubate at 37°C.  The reaction 
volume varied from 50-500 µL.  The incubation time period varied from 1 to 16 hours.  After 
incubation, the reaction was terminated at 100°C for 2 minutes then centrifuged at 16000 × g 
for 1 minute.  The supernatant was collected for an additional N-sulfonation step or dialyzed 
against 25 mM ammonium bicarbonate and dried by centrifugal evaporation for further 
analysis. 
Radioactive sulfotransferase assay- This protocol was followed for NST2, 2OST, 6OST2, 
3OST1, and 3OST5 and their respective substrates shown in Table VI  Approximately 5-10 
µg of Sulfotransferase, 0.5 to 1 ×106 cpm 3’-phosphoadenosine 5’-phosphosulfate 
([35S]PAPS), and 5-50 nmoles of unlabeled PAPS was added and the reaction was incubated 
at 37 oC for 1-4 hrs.  The reaction was heat deactivated in a 100 °C for two minutes.  Heparan 
polysaccharides were purified by DEAE ion exchange chromatography.  Briefly, the reaction 
mixture was diluted in 0.8 to 1 mL of a buffer containing 20 mM sodium acetate, 150 mM 
NaCl, 0.001% Triton X, and pH 5 and applied to a 0.2 mL DEAE column. The column was 
washed four times with 1 mL of UPAS buffer (20 mM sodium acetate, 150 mM NaCl, 3 M 
urea, 0.02% Triton X, pH 5) and re equilibrated  with 2 mL of the dilution buffer.  The 
column was eluted with 1 mL of 20mM sodium acetate, 1 M NaCl. The amount of 35S-
labeled polysaccharide was determined by scintillation counting (10% of the total eluent 
volume).  The remainder of the eluent was dialyzed against 20 mM ammonium bicarbonate 
overnight at 4 °C.  The dialyzed polysaccharide solution was dried by centrifugal evaporation 
and reconstituted in water for further use.   
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Table 4.  Summary of the substrates used in radioactive sulfotransferases reaction
Enzyme Substrate
NST HS or DeAcK5Pa
2OST CDNSHpb
6OST1 CDNSHpb
3OST1 HS
3OST5 HS
a. DeAcK5P is completely deacetylated capsular K5 polysaccharide
b. (CDSNS) is completely desulfonated re-N-sulfonated heparin.
Polysaccharide digestion by heparin lyases- Recombinant Heparin Lyase I, II, and III 
(Hep I-III) was used to depolymerize HS polysaccharides to yield disaccharides.  Briefly, 
purified polysaccharide was dissolved in buffer containing 40 mM ammonium acetate and 3 
mM CaCl2 to a final volume of 48 µL. Two microliters of purified Hep I-III (2 mg/ml in 
phosphate buffered saline) was added and the reaction was allowed to proceed overnight at 
37°C.  The reaction was heat deactivated and the supernatant was recovered for the 
disaccharide analysis.   
Preparation of 3OST5 Stable Expression Cells (3OST5/CHO)
The expression plasmid pcDNA3.1-3OST5 was transfected into wild type CHO cells using 
LipofectAMINE 2000 (Invitrogen, Inc.) following the manufacturer’s protocol.  Six days 
after the transfection, the cells were trypsinized and transferred into a 6 x 8 well plate at the 
concentration of 0.5 cells per well.  The cells were grown in F12 medium containing 10% 
bovine serum (from JRH Biosciences) and 1 mg/ml Geneticin (G418 sulfate, Invitrogen, 
Inc.) at 37oC under 6 % CO2 for two to three weeks until confluence was attained.
RT-PCR and Northern blot analysis- mRNA were purified from CHO-K1 and 
3OST5/CHO cells using the kits from Qiagen.  From two T75 flasks of confluent CHO-K1 
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and 3OST5/ CHO cells, we obtained 3.0 µg and 3.3 µg of mRNA, respectively.  RT-PCR 
analysis was carried out using Omniscript RT kit (Qiagen) with two 3-OST-5 specific 
primers: 5’-primer GAGCCCGCACTCAGGCTGAATTCCC, 3’-primer AAATCTAG 
AGGGCCAGTTCAATGTCCT8.  For northern blot analysis, mRNAs were resolved on 1.2% 
formaldehyde-agarose gel and blotted to Hybond-XL membrane (Amersham) using an 
electrotransfer approach.  The coding sequence of 3OST5 was labeled with [ -32P]dCTP in a 
reaction with Klenow enzyme (Roche Molecular Biochemicals) and used as a probe to 
hybridize the Human Multiple Tissue Northern (MTN®) blot (CLONTECH). The 
hybridization was carried out in ExpressHyb Hybridization Solution (CLONTECH) at 60 °C 
for 1 h, and the blot was washed with 0.1× SSC containing 0.5% SDS at 60 °C for 40 min
(where 1× SSC contains 150 mM NaCl and 15 mM sodium citrate, pH 7.0). The membrane 
was exposed to an x-ray film for 4 days.
HS Polysaccharide Structural Analysis
Degradation of N-deacetylated  heparosan by nitrous acid-  NDase-treated [3H]heparosan 
was depolymerized by nitrous acid degradation at pH 4.5.  Briefly, polysaccharides were 
dried by centrifugal evaporation and the resultant oligosaccharides were reduced with NaBH4
in 0.1N NaOH at 50°C and resolved by size exclusion on a Biogel P6 column (0.5 × 200 cm) 
equilibrated with 500 mM ammonium bicarbonate at a flow rate of 3 mL/hour. Fractions of 
approximately 0.8 mL were collected and radioactive content was determined by scintillation 
counting. 
8
 The 3	-primer contains a XhoI site, which does not belong to the sequence of 3OST5. The 3OST5 sequence in 
this primer is AGGGCCAGTTCAATGTCCT.
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Determination of the distribution of N-sulfated glucosamine residue in HS- [3H, 35S]HS 
from 3OST5/CHO and wild-type CHO were depolymerized by HS specific nitrous acid (pH 
1.5) cleavage.  The resulting oligosaccharides were reduced with 0.5 M sodium borohydride 
in 0.1 N sodium hydroxide (Shively and Conrad, 1976) and then resolved on a Bio-gel P-6 
column (0.5 × 200 cm, from BioRad) equilibrated with 0.5 M ammonium bicarbonate at a 
flow rate of 3 ml/h. The void volume was measured by co-eluting dextran blue (average mol 
wt = 2 × 106 Da). 
Reverse phase ion pairing HPLC (RPIP-HPLC) of non-sulfated disaccharides- Resultant 
disaccharides from the Hep III digestion were separated on a C18 column (0.46 × 24 cm, 
Vydac) using an isocratic mobile phase of 1.5% acetonitrile, 9.5 mM ammonium phosphate, 
0.5 mM phosphoric acid, and 1 mM tetrabutylammonium (TBA) dihydrophosphate (Fluka) 
at a flow rate of 0.5 mL/min.  Fractions of 0.5 mL were collected and 3H radioactive material 
was detected by scintillation counting.  A standard curve correlating molar quantity and UV 
absorbance (at 232nm) of UA-GlcNAc standard (Simga) was also determined by RPIP-
HPLC. An aliquot of prepared cold and 3H-labeled heparosan was digested with HepIII, 
analyzed by RPIP-HPLC, and its quantity determined using the standard curve. 
RPIP-HPLC of sulfated disaccharides- HS was cleaved with nitrous acid (pH 1.5) and 
reduced with sodium borohydride as described by Shively and Conrad (Shively and Conrad, 
1976).  The disaccharides were analyzed by reverse phase ion pairing RPIP-HPLC (Liu et al., 
1999).  Briefly, a C18 reverse phase column (Vydac) was equilibrated with 38 mM 
ammonium dihydrogen phosphate, 2 mM phosphoric acid and 1 mM TBA dihydrogen 
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phosphate and eluted with acetonitrile at 8% for 45 minutes, at 15% for 15 minutes, and at 
19.5% for 30 minutes in a solution containing 38 mM ammonium dihydrogen phosphate, 2 
mM phosphoric acid, 1 mM TBA dihydrogen phosphate at a flow rate of 0.5 ml/min.  The 
identities of the disaccharides were confirmed by co-elution of 35S-labeled and 3H-labeled 
disaccharide standards.
HS/Protein Interactions Biochemical Assays
AT affinity fractionation- Approximately 5 × 106 cpm of [35S]HS was incubated with 5 µg 
AT in 50 µl of reaction buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM sodium 
chloride, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 µM dextran sulfate, 0.02 % sodium azide
and 0.0004 % Triton X-100 for 30 minutes at room temperature.  100 µl of 1:1 slurry of aged 
ConA-Sepharose (see General Procedures for the aging process) was added, and the reaction 
was agitated for one hour at room temperature on an orbital shaker.  The beads were washed 
three times with the reaction buffer and eluted with buffer containing 10 mM Tris-HCl (pH 
7.5), 1000 mM sodium chloride, 1 mM Mn2+, 1 mM Mg2+, 1 mM Ca2+, 10 µM dextran 
sulfate, 0.02% sodium azide, and 0.0004% Triton X-100. 
Determination of the binding affinity by affinity co-electrophoresis- The dissociation 
constant (Kd) of 3OST5/CHO antithrombin-binding HS and AT was determined using 
affinity co-electrophoresis, with the detailed procedures described elsewhere (Lee and 
Lander, 1991; Liu et al., 2002).  Approximately 7 × 104 cpm of antithrombin-binding [35S]HS
isolated from 3OST5/CHO cells was loaded per lane with zones of AT at the following 
concentrations 0, 1.5, 3.8, 7.5, 15, 31, 75, 125, and 250 nM.  The gel was performed at 400 
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mA for ~ 6 hours, dried, and analyzed on a PhosphoImager (Amersham Biosciences, Storm 
860).  The retardation coefficient was calculated as R= (M0-M)/M, where M0 is the mobility 
of free [35S]HS through each AT zone, and M is the mobility of bound [35S]HS through each 
separation zone.  The retardation coefficient was then plotted against the retardation 
coefficient divided by the concentration of AT.  The slope of the line represents -1/ Kd. 
Assay for the AT-mediated deactivation of factor Xa by HS- The procedures were 
modified from a report by Zhang and colleagues (Zhang et al., 1998).  HS was prepared from 
wild-type CHO-K1 and 3OST5/CHO in a similar fashion as described above, including 
treatment with 20 mU of chondroitinase ABC prior to ethanol precipitation.  The 
concentration of the HS isolated was determined by using Alcian blue (Bjornsson, 1993).  A 
final concentration of 27 µM AT was prepared with 1 mg/ml BSA in 1 x PBS.  Factor Xa 
(0.1 µM) was prepared with 1 mg/ml BSA in 1 x PBS.  Various amounts of HS, 0.5, 1.0 , 1 
0.5, and 2.0 µg of the HS from CHO/3OST5 and 1, 2, 3, and 5 µg of the HS from wild-type 
CHO, were dissolved in 20 µl of buffer containing 50 mM Tris, 7.5 mM Na2EDTA, 175 mM 
NaCl, pH 8.4 (buffer containing no HS was used as a control).  The mixture (25 µl) of the 
AT and factor Xa preparations were incubated with HS from CHO-K1 and 3OST5/CHO for 
4 minutes at 37oC followed by the addition of 25 µl of 1 mM S-2765 chromogenic substrate 
(Diapharma) and 1 mg/ml polybrene (Sigma).  The absorbance of the reaction mixture was 
measured at 405 nm continuously for 2 minutes.  The initial rate of absorbance was derived 
from the slope of the fitted curve for each data set.  These initial rates at varying HS 
concentrations were converted to an activity percentage based on the initial rate of the 
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reaction without HS (activity % = v0,sample / v0,control × 100%).  The ratios were plotted against 
HS concentrations and a best fit curve was used to determine an IC50 value. 
The binding of the cells to fluorescently labeled AT- The procedures for the preparation of 
fluorescently labeled AT were carried out as described by Zhang and colleagues (Zhang et 
al., 2001a) with minor modifications.  Briefly, AT (1 mg/ml) was incubated with 
neuraminidase (0.04 mU/µl, Worthington) and galactose oxidase (40 mU/µl, Worthington) in 
a buffer containing 25 mM sodium phosphate and 0.3 mM calcium chloride (pH 6.5) at room 
temperature for 1 hr.  The sample was then mixed with fluorescein hydrazide (0.8 mg/ml, 
Molecular Probes) and incubated at 4oC overnight.  The fluorescently labeled AT was 
purified by passing through a 200-µl heparin-Sepharose (Amersham) column, and the labeled 
AT was eluted with a buffer containing 1.5 M NaCl, 100 mM Na2HPO4, 27 mM KCl, and 18 
mM KH2PO4 (pH 7.3).  To stain the cells with fluorescently labeled AT, CHO-K1 and 
3OST5/CHO cells were plated on a chamber slide plate at 5×104 cells per well.  The cells 
were incubated in the growth media at 37oC overnight under 6% CO2.  The cells then were 
incubated in cold F12 media supplemented with 0.1% FBS containing 5 µg/ml of 
fluorescently labeled AT with or without 1,250 µg/ml unlabelled AT for 1 hr.  The cells were 
washed with cold 1 x PBS and fixed with 3.7% formaldehyde in PBS.  Cells were viewed 
with a microscope (Leica Diaplan, Leitz Weltzar, Germany) equipped for epifluorescence 
with a 100× objective, and images were captured using an Orca ER camera (Hamamatsu 
Corp.) controlled by SimplePCI imaging software (Compix Inc.).  The data were exported as 
8-bit TIFF files and processed using Adobe Photoshop.
Chemoenzymatic Synthesis of Heparin Analogues
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Preparation of immobilized HS sulfotransferases- Dialyzed sulfotransferases (4 ml, 4 
mg/ml) in PBS buffer (15 mM NaH2PO4, 30 mM Na2HPO4, 400 mM NaCl, pH 7) was mixed 
with 2 ml Aminolink@ plus beads (Pierce, IL) pre-equilibrated in PBS and 40 µL of 5 M 
sodium cyanoborohydride in 0.1M M sodium hydroxide in a small fritted column (Pierce or 
Bio-Rad).  The mixture was then subjected to end over end rocking for six hours at room 
temperature.  The column was eluted and washed with 3 column volumes of PBS.  To 
quench active functional groups of the agarose beads, the column was washed with two 
column volumes of a 1 M Tris-HCl, 0.05% sodium azide, pH 7.4 quenching buffer. An 
additional 2 mL of the quenching buffer along with 40 L of sodium azide solution was added 
to the column and subjected to an additional 30 minutes of end over end rocking at room 
temperature.  The solution was eluted and the column was washed with 10 column volumes 
of a wash solution containing 1M NaCl and 0.05% sodium azide.  The column was stored in 
PBS with 0.05% sodium azide.  The immobilization efficiency was assessed by comparing 
protein concentration by UV spectrometry (at 280 nm) of dialyzed flow through with the 
starting material.  Immobilized enzyme was washed with 50 mM MES, 1% Triton X-100, 1 
mM MgCl2, and 1 mM MnCl2, pH 7.0, and stored at 4oC.
Measurement of enzymatic activities of immobilized proteins- To determine the activity of 
6OST and 2OST, completely desulfonated re-N-sulfonated (CDSNS) heparin was used as a 
substrate (Figure 18).  Immobilized proteins (100 µl, 
300 µg immobilized enzyme) with 100 
µg substrate (HS for 3OST, and CDSNS heparin for 2OST or 6OST1) and 200 µM 
[35S]PAPS ( 1000 cpm/pmole) in 1 ml of 50 mM MES, pH 7.0, 1% Triton X-100, 1 mM 
MgCl2, and 1 mM MnCl2.  After rotating at room temperature for 1 h, the supernatant was 
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collected, and the beads were washed with 3 × 200 µl of 1 M NaCl in 25 mM sodium acetate 
(pH = 7.4).  The supernatant and washes were combined, diluted with 2 ml water and 
subjected to the DEAE chromatography to determine the amount of [35S]HS product used to 
determine the activities of the various HS O-STs.
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Figure 18. Completely desulfonated re -N-sulfonated heparin (CDSNSHp). This polysaccharide serves as 
substrate for both 2OST and 6OST. 
2OST modification of N-sulfo K5  polysaccharides- Epimerase at 500 µg/mL was 
incubated with 200 µg/mL of K5NS in 50 mM MES, pH 7.0, 1% Triton X-100, 1 mM 
MgCl2, and 1 mM MnCl2 at 37°C for approximately four hours with end over end rotation.  
The reaction was then cooled to room temperature and 2-3 mg of purified AST-IV was 
incubated with 40 µM PAP and 10 mM PNPS at 25oC for 30 min at a final volume of 5 mL. 
The reaction mixture was mixed with 4 ml of the immobilized sulfotransferase and rotated at 
25°C for 24 h.  The supernatant was recovered, and the polysaccharide that bound to the 
beads was eluted by washing two times with 5 mL of 1 M NaCl in 20 mM sodium acetate.  
Both the supernatant and wash were combined and diluted at least 5 times with 20mM 
sodium acetate, 50 mM NaCl, 0.001% Triton X, pH 5 and applied to a 1 mL DEAE (fast 
flow Amersham) column.  The column was washed with 20 column volumes of UPAS buffer 
(20 mM sodium acetate, 150 mM NaCl, 3 M urea, 0.02% Triton X, pH 5) and eluted with 2 
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mL of 20mM sodium acetate, 1 M NaCl. The eluent was dialyzed against 20 mM ammonium 
bicarbonate overnight at 4 °C.  The dialyzed polysaccharide solution was dried by centrifugal 
evaporation and reconstituted in water.   
Chapter III. BIOSYNTHESIS OF ANTICOAGULANT HEPARAN SULFATE BY 
3OST ISOFORM 5
    In this study, we utilized Chinese hamster ovary (CHO) cells as a model system to study 
the biosynthesis of antithrombin-binding HS by 3OST5. We have generated a CHO cell line 
that stably expresses the human 3OST5 gene (3OST5/CHO). We demonstrate that 
3OST5/CHO cells can generate AT-binding HS that has a similar affinity for AT as 3OST1 
modified HS. In addition, we demonstrate that HS isolated from 3OST5/CHO cells has the 
capacity to accelerate the inhibitory effects of AT on factor Xa. These findings suggest that 
3OST5 may contribute to hemodynamic processes in vivo.
AT- and gD- binding to HS- The AT-binding and gD immunoprecipitation assays are used 
for measuring the fraction of heparan sulfate that binds to either protein.  These experiments 
are proven indicators of biological function of 3-O-sulfated HS (i.e. thrombin and factor Xa 
deactivation or HSV1 entry).  In Figure 19, HS modified by 3OST1 shows a 38.8 fold 
increase in AT-binding over the control, but only a 5.25 fold increase in gD binding over the 
control.  HS modified by 3OST3 shows only a 1.2 fold increase in AT binding over the 
control, and a 23.5 fold increase in gD binding over the control.   HS modified by 3OST5 
shows both a 39.6 fold increase in AT binding over the control, as well as a 20.8 fold
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increase in gD binding over the control.  The increases in bound modified HSs reflect their 
capacity to activate AT and/or serve as an entry receptor for HSV1.  3OST5 is unique in its 
ability to generate both gD and AT binding HS.  We sought to generate a CHO cell line that 
stably expresses 3OST5 in order to assess its contribution in the HS biosynthetic pathway 
and to more extensively characterize the anticoagulant activity of 3OST5 modified HS.
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Figure 19. 3OST5 modified HS binds to both AT and gD. The binding of the HS and gD was determined by 
incubating modified [3H, 3-O-35S]HS with gD followed by immunoprecipitation using anti-gD monoclonal 
antibody (DL6) to precipitate the complex of HS and gD. The percentages binding to gD and AT were 
calculated based on 3H-counts. Data are presented as the mean ± range (or SD); n represents the number of 
determinations.  The binding of the HS and AT was determined by incubating modified HS and AT by using 
AT/ConA-Sepharose beads.  The control was [3H]HS without enzymatic modifications.  3OST1, 3OST3, and 
3OST5 modified HS were prepared by incubating [3H]HS (from CHO K1 cells), [35S] PAPS, and purified 
3OST1 (70 ng), 3OST3 (35 ng), and 3OST5 (70 ng), respectively. 3OST1, 3OST3, and 3OST5 are all 
recombinant enzymes from insect cells.
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Determination of the expression of 3-OST-5 in 3OST5/CHO cells- In order to study the 
role of 3OST5 in synthesizing anticoagulant HS in vivo, we transfected 3OST5 cDNA into 
wild type CHO cells to obtain a stable expression of 3OST5 (3OST5/CHO).  A total of 12 
clones were isolated and screened for the expression of 3OST5 by analyzing the structure of 
the HS from each clone as described under “METHODS”.  We chose clone 9 in this study 
and designated the clone as 3OST5/CHO.   The results of the analyses of the level of 3OST5 
mRNA in 3OST5/CHO cells are shown in Figure 20.  A Northern blot analysis reveals a 
strong signal at 1.1 Kb, which is very close to the expected size for the 3OST5 coding region 
of the transfected plasmid (1.06 Kb), whereas the signal was undetectable in the mRNA from 
wild type CHO (Figure 1A). Using reverse transcriptase-PCR approach, we observed a
product at 0.9 Kb, which is identical to the expected size using two 3OST5 specific primers, 
whereas the PCR product is absent in the mRNA from wild type CHO cells (Figure 1B).  
These results indicate that the level of 3OST5 mRNA is substantial in the stable expression 
cells, while it is absent in wild-type cells (CHO-K1).  How the production of 3OST5 
transcripts in the stable cell lines compares with that of other cell lines was not explored. 
Empirical evidence suggests that high mRNA levels of the 3OSTs do not translate into high 
protein expression (Deepak Shukla, correspondence).  This may underscore the potential for 
translational control of 3OST expression [analogous to the NDSTs (Grobe and Esko, 2002)] 
and the need for cells to regulate the level of 3-O-sulfated HS production.    
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Figure 20. Northern blot and RT-PCR of 3OST5/CHO. (A) Northern blot analysis of wild-type CHO cells 
and 3OST5/CHO cell line expressing the 3-OST-5 gene. About 2 µg of mRNA from wild-type CHO and 
3OST5/CHO cells was loaded into the agarose gel and blotted. The blot was hybridized with a 32P-labeled 
3OST5 probe as described under Materials and methods. (B) RT-PCR analysis of the mRNA from 3OST5/CHO 
cells (lanes 1 and 2) and from wild-type CHO (lanes 3 and 4). We used 26 ng (lane 1) and 52 ng (lane 2) of 
mRNA from 3OST5/CHO cells, and 24 ng (lane 3) and 48 ng (lane 4) of mRNA from wild-type CHO cells for 
the RT-PCR analysis.
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3OST5/CHO generate multiple 3-O-sulfated disaccharides- In order to confirm that 
3OST5/CHO cells biosynthesize 3-O-sulfated HS, we conducted the disaccharide analysis of 
metabolically labeled HS isolated from 3OST5/CHO cells and CHO-K1 cells.  The [35S]HS 
were degraded by nitrous acid (pH 1.5) followed by sodium borohydride reduction.  The 
RPIP-HPLC chromatograms of the disaccharide analysis for HS from CHO-K1 and from
3OST5/CHO are shown in Figure 21.  As expected, the characteristic disaccharides, 
IdoUA2S-AnMan3S, GlcUA-AnMan3S6S, and IdoUA2S-AnMan3S6S, of 3OST5 modified 
HS were observed in HS from 3OST5/CHO (Figure 21B) (Xia et al., 2002) .  In addition, we 
also observed the disaccharide IdoUA-AnMan3S6S, which is another characteristic 
disaccharide from 3OST5 modified HS (Chen et al., 2003).  None of these 3-O-sulfated 
disaccharides were present from nitrous degradation of the HS from wild-type CHO where 
the major disaccharide was IdoUA2S-AnMan6S (Figure 21A), a common disaccharide in 
HS.  
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Figure 21. RPIP-HPLC chromatograms of the disaccharide analysis of HS. Metabolically labeled [35S]HS 
from (A) wild-type CHO and (B) 3OST5/CHO were treated with nitrous acid (pH 1.5) followed by sodium 
borohydride reduction. The disaccharides were desalted and resolved by RPIP-HPLC. The elution positions of 
disaccharide standards are indicated by 1: IdoUA2S-AnMan3S, 2: IdoUAAnMan3S6S, 3: GlcUA-AnMan3S6S, 
4: IdoUA2S-AnMan6S and 5: IdoUA2S-AnMan3S6S. Insets represent the enlarged region where disaccharides 
2 and 3 were eluted. The 35S-peak eluted at 8 min of panel B is likely to contain both free [35S]sulfate and a 
small amount of 35S-disaccharide. This additional peak is probably due to high concentration of salt during the 
sample preparation.
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Effects of 3OST5 overexpression on HS structure- To investigate whether expression of 
3OST5 gene affected the distribution of N-sulfated glucosamine residues within the HS, we 
compared the oligosaccharide compositions of HS isolated from both CHO-K1 and 
3OST5/CHO after nitrous acid degradations at pH 1.5.  The BioGel P-6 profiles of nitrous 
acid degraded (pH 1.5)-[3H, 35S]HS from CHO-K1 and 3OST5/CHO were shown in Figure 
22, and the calculated relative percentages of the oligosaccharides with different sizes were 
shown in Table V. Chondroitin sulfate polysaccharide, which is a contaminant in the 
preparation of [3H,35S]HS, was not susceptible to nitrous degradation, and migrated at the 
void volume of the P-6 column.  We observed that the percentages of disaccharides and 
tetrasaccharides from nitrous acid-degraded HS of 3OST5/CHO was similar, compared to 
that of wild type CHO cells.  The result suggested that the expression of 3OST5 has not 
significantly altered the distribution of N-sulfated glucosamine residues of HS.
Table 5. Relative percentages of oligosaccharides resulted from nitrous acid degraded 
HS from 3OST5/CHO and from wild-type CHO 
[3H]a [35S]a
HS Oligosaccharides CHO 3-OST-5/CHO CHO 3-OST-5/CHO
Di- 15 % 13 % 75 % 74 %
Tetra- 18 %          14 % 9 % 9 %
Hexa- 7 % 8 % 3 % 3 %
Octa- 11 % 8 % 2 % 3 %
a. Relative amounts of oligosaccharides generated by low pH nitrous degradation were estimated based on the 
total dpm of [3H] and [35S]  for each sample excluding the CS peaks.  
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Figure 22. 3OST5/CHO N-sulfo domains do not vary from wild CHO. Profiles of nitrous-degraded [3H, 
35S]HS on BioGel P-6. [3H, 35S]HS polysaccharide from wild-type CHO and stable cell line was treated with 
nitrous acid (pH 1.5) and reduced with sodium borohydride. The resultant oligosaccharides were resolved on a 
BioGel P-6. Panel A represents 3H profile (—•—) and 35S profile (—
—) from wild-type CHO cells. Panel B 
represents 3H profile (—•—) and 35S profile (—
—) from 3OST5/CHO cells. The void volume, measured by 
the elution of dextran blue, was not included in the profiles. The peaks observed in the early fractions of 35S 
profiles are undigested chondroitin sulfate.
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Binding affinity of HS from 3OST5/CHO with AT- The dissociation constant (Kd) of AT-
binding HS for AT was determined by affinity co-electrophoresis, a method employed in 
several studies investigating HS/protein interactions (Lee and Lander, 1991; Liu et al., 2002).  
The AT-binding HS was isolated from metabolically labeled [35S]HS of 3OST5/CHO by AT-
affinity fractionation.  The picture of the gel and Scatchard analysis of the gel were shown in 
Figure 23.  Our analysis revealed that HS from the CHO/3OST5 cell line has a Kd of 10 nM 
with AT.  It is important to note that the binding affinity of 3OST1 modified HS from CHO 
cells and AT was determined to be 32 nM (Zhang et al., 2001b) , and the binding affinity of 
heparin and AT was determined to be 9 nM (Lee and Lander, 1991).  These results  suggest 
that 3OST5 modified HS has a similar binding affinity for AT relative to previously 
characterized anticoagulant HS.  
3OST5 modified HS promotes AT mediated deactivation of factor Xa- The serine protease 
factor Xa of the blood coagulation cascade plays a key role in regulating the formation of 
fibrin, a major constituent of blood clots.  HS present on the blood vessel wall prevents blood 
from clotting by inhibiting the activity of factor Xa and other serine proteases via its 
interaction with AT.  We investigated whether the binding of the HS from 3OST5/CHO cells 
to AT inhibits the activity of factor Xa by using a method described by. (Zhang et al., 
2001b).  Figure 24 shows the inhibition curve of the activity of factor Xa by HS with an IC50
value of 10 µg/ml for the HS from 3OST5/CHO cells, whereas approximately 70% of the 
factor Xa activity remained in the presence of 50 µg/ml from wild type CHO cells, 
suggesting the IC50 value for the HS from wild type CHO cells is greater than 50 µg/ml.  
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Figure 23. Determination of Kd by affinity co-electrophoresis. The top panel represents an autoradiograph of 
the agarose gel in which 650,000cpm of AT-binding [35S]HS from 3OST5/CHO was subjected to 
electrophoresis through zones containing AT at the concentrations indicated. The Scatchard plot of data was 
obtained from the autoradiograph.  A plot of R/[AT]total versus R, where the retardation coefficient R = (M0 − 
M)/M0. M0 is the migration of free [35S]HS, and M is the observed migration of [35S]HS in the presence of AT. 
Assuming that [35S]HS and AT forms a 1:1 complex and AT is in great excess, this plot should yield a straight 
line with a slope of −1/KD according to the Scatchard equation. 
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Thus, the HS from 3OST5/CHO is at least five times more potent inhibitor than the HS from
wild type CHO cells.  We anticipated seeing a greater difference in IC50 values for HS from 
3OST5/CHO cells and the HS from wild type CHO cells. However since we used total HS 
(without AT-affinity fractionation) in this experiment, the concentration of anticoagulant HS 
was diluted by the non-anticoagulant HS in the preparation.  Ideally, AT-binding HS should
have been purified in order to carry out this study.  However, only approximately 7-8% of the 
HS isolated from 3OST5/CHO are antithrombin-binding HS.  We typically obtained 2 to 3 
µg of HS from a T75 flask.  Based on this yield, it would have been technically difficult to 
obtain a sufficient amount of antithrombin-binding HS and to determine its concentration by 
the Alcian blue assay in order to carry out additional experiments. 
HS concentration (µg/mL)
0 10 20 30 40 50
A
ct
iv
ity
 
%
0
20
40
60
80
100
120
Figure 24. The inhibition of factor Xa activity by HS. HS isolated from 3OST5/CHO (—•—) and isolated 
from wild-type CHO (—
—) at varying concentrations were incubated with a reaction mixture consisting of 10 
µM antithrombin, 40 nM factor Xa, 14 mM Tris–HCl, 2 mM Na2EDTA, 50 mM NaCl. The reaction was 
stopped with a 25-µl solution containing 1 mg/ml polybrene and 1 mM S-2765 chromogenic substrate. The 
activity of factor Xa was then determined by monitoring the increase of the absorbance at 405 nm as described 
under “METHODS”. Each data point represents the average of two determinations. Error bars indicate the 
range.
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Comparing the cell surface antithrombin-binding sites between 3OST5/CHO cells and CHO-
K1 cells- Given the fact that HS is believed to be present on the surface of the cells to serve 
as a natural anticoagulant, we wanted to confirm that the antithrombin-binding HS that is 
synthesized by 3OST5 is indeed present on the cell surface. To this end, we compared the 
binding of fluorescently labeled AT to 3OST5/CHO cells and wild type CHO-K1 cells.  
Fluorescently labeled AT was incubated with the cells at 4oC, and the cells were washed with 
PBS to remove unbound fluorescently labeled AT followed by fixing the cells with 
formaldehyde.  The cells were then visualized by fluorescence microscopy as depicted in 
Figure 25.  It is apparent that the fluorescent intensity was substantially higher for 
3OST5/CHO cells than that for CHO-K1, suggesting that an increase number of AT-binding 
sites on the surface of 3OST5/CHO.  In addition, the fluorescent intensity was decreased by 
using 250-fold in molar excess of unlabeled AT, suggesting that the observed fluorescent 
signals were due to the binding of cell surface HS to AT. Taken together, our results 
suggested that 3OST5 cDNA is capable of generating cell surface HS that binds to AT.  
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Figure 25. Binding of fluorescently labeled AT to 3OST5/CHO and wild-type CHO cells. Fluorescently 
labeled AT was incubated with the cells in the presence or absence of 250-fold molar excess of unlabeled AT. 
Panels A and B are micrographs of 3OST5/CHO cells and wild-type cells, respectively. Upper panels are 
fluorescent micrographs of cells using identical image intensity settings. Lower panels depict phase-contrast 
image of cells. Panel C shows 3OST5/CHO cells in the presence of 250-fold molar excess of unlabeled AT.
fluorescence
phase
A B C
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Conclusions- 3OST5 cDNA was introduced into wild type CHO cells to study the role of 
3OST5 in synthesizing anticoagulant HS in cell culture.  Results from Northern analysis and 
RT-PCR revealed high levels of expression of 3OST5 in the stable cell line 3OST5/CHO.  
The fraction of 3OST5/CHO HS that binds to AT was 24-fold greater than that of wild-type 
CHO HS.  From these results we concluded that a stable expression of 3OST5 in 
3OST5/CHO cells was obtained.  We found that the expression of 3OST5 was constant for at 
least five passages (data not shown) as determined by the level of 3-O-sulfated disaccharides.  
The characteristic disaccharides of HS generated by purified enzyme, IdoUA2S-
AnMan3S±6S, IdoUA-AnMan3S6S, and GlcUA-AnMan3S6S, are consistent with those 
observed in the HS from 3OST5/CHO cells.  However, it is not known whether the 
saccharide sequences at the oligosaccharide level from in vivo and in vitro synthesis around 
the 3-O-sulfated glucosamine residue are identical.  Such conclusions would require an in 
depth structural analyses of the oligosaccharides.  It should be noted that 3OST5 modified 
HS that is generated by purified 3OST5 enzyme in vitro also contains two monosulfated 
disaccharides, GlcUA-AnMan3S and IdoUA-AnMan3S, although those only represent a 
small portion of 3-O-sulfated disaccharides (Chen et al., 2003).  We did not investigate 
whether those monosulfated disaccharides are present in HS from 3OST5/CHO as it was not 
the focus of the current study.
Antithrombin inhibits the activities of factor Xa and thrombin, which is a major 
mechanism in regulating the blood coagulation process.  The process is primarily dependent 
on the formation of a complex between AT and cell surface HS (Conrad, 1998).  In order to 
link 3OST5 modified HS and potential anticoagulant activity in vivo, the location of 3OST5 
modified HS and the binding affinity of 3OST5 modified HS were investigated.  Using 
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fluorescently labeled AT, we established that AT-binding HS is indeed present on the surface 
of 3OST5/CHO.  In addition, we concluded that the binding affinity of 3OST5/CHO HS is 
very similar to that of the HS modified by 3OST1 and heparin.  Furthermore, we 
demonstrated that 3OST5 modified HS can serve as a potent cofactor in the AT mediated 
inhibition of factor Xa.  Taken together, our results suggest that 3OST5 is capable of 
generating a natural anticoagulant on the surface of the cells, which is similar to the proposed 
function of 3OST1 (Shukla et al., 1999).  While 3OST1 was reported to be expressed in 
human umbilical vein endothelial cells (Shukla et al., 1999), we did not detect the expression 
of 3OST5 in primary human umbilical vein endothelial cells by Northern and RT-PCR (data 
not shown). 
3OST5 has limited expression in human muscle, fetal brain, and adult brain tissues (Xia et 
al., 2002) (Mochizuki et al., 2003).  Northern analyses of the previously discovered 3OSTs 
have shown them to be expressed at only minute levels in skeletal muscle.  It is known that 
3OST1 modified HS and 3OST3 modified HS have distinct biological functions (Shworak et 
al., 1997).  The lack of additional 3OSTs in skeletal muscle may be compensated for by the 
unique substrate specificity of 3OST5, which generates the 3-O-sulfated HS with various 
biological activities.  The relationship between the presence of anticoagulant HS and the 
functions of skeletal muscle is unclear.  One strong possibility is that 3-O-sulfated HS 
contributes to a variety of physiological processes besides anticoagulation.  The literature 
suggests that 3-O-sulfated HS is involved in binding to growth factor and growth factor 
receptor (Liu and Rosenberg, 2002) (McKeehan et al., 1999).  However, whether 3OST5 
modified HS binds to the growth factors and growth factor receptors is still unknown.  
Additionally, the study by (HajMohammadi et al., 2003) revealed that a tissue homogenate 
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from 3OST1-/-  mouse brain maintained both the capacity to generate antithrombin-binding 
HS and anti-Xa activity.  Although both isoforms are shown to be expressed in brain, it is 
difficult to discern whether these residual levels of AT-binding HS are the result of 
simultaneous 3OST5 and 3OST1 expression and activity or perhaps the result of the 
additional 3OSTs compensating for the lost expression of 3OST1.  
In summary, this study has provided a biochemical basis for the generation of AT-
binding HS by a recently discovered member of the HS 3OST family. Our results indicate 
that the HS structure generated by 3OST5 has the capacity to bind to AT with high affinity 
and neutralizes the activity of factor Xa, a key component of the blood coagulation pathway.  
Further characterization of this enzyme and the HS structures that it generates may provide 
insight into its roles in cardiovascular physiology/pathology and perhaps the design of novel 
approaches towards synthesis of relevant HS oligosaccharides.  
Chapter IV.  LOCALIZATION AND CHARACTERIZATION OF THE N-
DEACETYLASE DOMAIN OF NDST2
    NDST is a type II membrane bound protein consisting of 883 amino acid residues.  The 
expression and characterization of NDST isoforms have been reported in mammalian, insect,
and yeast expression systems (Berninsone and Hirschberg, 1998; Kuberan et al., 2003c; 
Saribas et al., 2004).  It has been hypothesized that NDST has two functional domains, 
responsible for N-deacetylase and N-sulfotransferase activities, respectively.   The C-terminal 
N-sulfotransferase domain has been expressed and a crystal structure has been resolved, 
resulting in a major breakthrough towards defining the catalytic mechanisms and 
polysaccharide binding site of HS sulfotransferases (Kakuta et al., 1999).  Several failed 
attempts to express NDST in a bacterial system and the putative N-terminal N-deacetylase 
domain in a mammalian system have been noted in the literature (Berninsone and 
Hirschberg, 1998; Kusche- Gullberg and Kjellen, 2003; Saribas et al., 2004). Thus, whether 
the N-terminal domain of NDST is a functional domain with N-deacetylase activity remains 
in question.  Herein, we report the expression and characterization of the N -terminal domain 
of NDST-2 that retains N-deacetylase activity (NDase).  The expression of an NDase active 
construct should prove useful in further analysis of NDST mechanisms of action and 
potentially in chemoenzymatic synthesis of HS.
Expression and characterization of ND domain fusion protein- Full length human NDST2
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contains 883 amino acid residues contains both N-deacetylase and N-sulfotransferase 
activities (Eriksson et al., 1994).  It has been well documented that C-terminal domain of the 
NDST (599T-883G) maintains the N-sulfotransferase activity (Berninsone and Hirschberg, 
1998; Kakuta et al., 1999).  We hypothesized that N-deacetylase and N-sulfotransferase 
activities are located separately at the N-terminal and C-terminal domains of NDST1 protein.  
Therefore, expression of N-terminal domain of NDST2 should yield a functional protein with 
N-deacetylase activity.  We initially prepared a maltose binding protein-NDST2 fusion 
protein, and the resultant proteins contain both N-deacetylase/N-sulfotransferase activities 
(data not shown).  The expression was achieved in Origami B cells over-expressing the 
groES/EL chaperone proteins as described under “METHODS”.  We also prepared several 
truncated N-terminal domains of NDST2, including NDase1 (A66-P604), NDase2 (A66 -
T614), NDase3 (A66-L625), and NDase4 (A66-W594).  While all of these constructs were 
expressed, and it was determined that NDase1 gave the highest N-deacetylase activity.  We 
decided to further characterize the enzymatic activity of NDase1.  To simplify the protein 
purification, we introduced a (His)6 tag at the C-terminal of NDase1.  Thus, a C-terminal 
(His)6-tagged NDase1 construct has been used throughout this study.  
The N-deacetylase activity of the recombinant protein was determined by coupling 
with NST, which is outlined in Figure 26A.  Bacterial capsular polysaccharide of E. coli K5 
strain, heparosan, serves as a substrate for N-deacetylase as it is structurally similar to the 
heparin or heparan sulfate precursor (Eriksson et al., 1994).  Heparosan was incubated with 
NDase to generate N-unsubstituted glucosamine units (GlcNH2).  After heat deactivation of 
the NDase reaction, recombinant N-sulfotransferase (NST) and [35S]PAPS was added into the 
reaction mixture to sulfate GlcNH2 residues.  Under our reaction conditions, the rate of sulfo-
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transfer shows a linear increase relative to the amount of functional NDase present as shown 
in Figure 26B, suggesting that the amount of 35S-labeled heparosan correlates with the 
activity of NDase.  To our knowledge this represents the first time that the N-deacetylase 
activity has been detected in which the C-terminal N-sulfotransferase domain has been 
truncated from the full length NDST.
Figure 26. Determination of the activity of N-deacetylase activity.  The screening method for NDase activity 
is outlined in (A).  The NDase reaction was heat deactivated in a boiling water bath for 2 minutes.  The 
presence of free amino groups was then detected by converting them to N-sulfo groups by an exhaustive N-
sulfotransferase reaction.  In (B), a linear dose response is observed with the addition of increasing amount of 
NDase in a 50 µL reaction.
We also attempted to estimate the Km of NDase towards the heparosan.  We observed 
that the amount of N-unsubstituted glucosamine reached a plateau as determined by the 
susceptibility to the modification of NST (Figure 27A and 27B).  The Km was estimated at 
170 µg/mL.  This value is approximately two fold lower than reports using mastocytoma 
derived NDST constructs expressed in mammalian systems in which the traditional 
[3H]acetate release assay was used (Bame et al., 1991; Orellana et al., 1994), suggesting that 
bacterial expressed NDase has similar binding affinity toward heparosan as that of 
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mammalian cell expressed NDST.  Due to the fact that we indirectly measured the amount of 
GlcNH2 generated during the NDase digestion, we could not determine the Vmax of NDase 
towards heparosan.  
Figure 27. Determination of Km of NDase towards heparosan.  The NDase reaction was allowed to proceed 
for 45 minutes, followed by heat deactivation and then a NST reaction for 30 minutes.  The amount of N-
unsubstituted glucosamine unit (GlcNH2) was determined by measuring susceptibility to NST modification, as 
determined by the amount of [35S]sulfate transferred to the polysaccharide product.  
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Structural characterization of NDase-treated heparosan- To further confirm that NDase 
indeed generates the N-unsubstituted glucosamine unit in heparosan, a disaccharide and 
oligosaccharide analyses on the NDase-treated heparosan was performed.  To facilitate 
detection, we prepared metabolically 3H-labeled heparosan as a substrate as described under 
“Methods”.  For the disaccharide analysis, NDase treated [3H]heparosan was enzymatically 
cleaved with heparin lyase III.  We observed that greater than 90% of the 3H-labeled 
compound migrated as disaccharides on BioGel P-2 (data not shown).  The resultant 
nonsulfated disaccharides were resolved by reverse phase ion pairing HPLC.  As shown in 
Figure 28, approximately 6% of the recovered disaccharides are UA-GlcNH2, whereas this 
disaccharide is undetectable in the control (unmodified [3H]heparosan).  This result 
confirmed that NDase has the anticipated enzymatic activity.  The degree of deacetylation 
typically ranged between 5-20% and depended on both reaction time and the amount of 
NDase used.  
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Figure 28. Disaccharide analysis of NDase-treated heparosan.   Heparosan (A) and NDase-treated heparosan 
(B) were digested with heparin lyase III at 37 ºC and the reaction was carried out overnight to ensure 
completeness.  The reaction was heat deactivated, centrifuged and the supernatant (25 µL) was diluted in buffer 
containing 9.5 mM ammonium phosphate, 0.5mM phosphoric acid, and 67 mM tetrabutylammonium phosphate 
(250 µL final volume).  The sample was then analyzed by RPIP-HPLC as described in “Methods”.  Arrow 1 
indicates UA-GlcNH2 and arrow 2 indicates UA-GlcNAc
84
Distribution of N-deacetylated glucosamine residues in NDase treated heparosan-
In order to determine the position of GlcNH2 units within the NDase modified heparosan, an 
overnight NDase reaction was performed and the resultant [3H]deacetylated heparosan was 
subjected to nitrous acid deamination at pH 4.5.  This reaction specifically cleaves the 
glycosidic linkage between deacetylated glucosamine and hexuronic acid (Shively and 
Conrad, 1976).  The resulting oligosaccharides were resolved by gel permeation 
chromatography and the distribution of GlcNH2 units can be determined (Figure 29).  Our 
results reveal that heparosan (without NDase treatment) is resistant to the nitrous acid 
degradation (Figure 4A).  On the contrary, NDase-treated heparosan was susceptible to 
nitrous acid degradation, suggesting that N-unsubstituted glucosamine residue is present in 
the NDase-treated heparosan (Figure 4B). We observed that approximately 10% of the 
oligosaccharides eluted as disaccharides and 30% as  hexasaccharide.  These results 
demonstrate that the disaccharide unit GlcUA-GlcNH2 generated by NDase can be clustered 
as evidenced by that fact that about 10% of the total oligosaccharides migrated as a 
disaccharide.  In addition, the disaccharide GlcUA-GlcNH2 is also separated by different 
numbers of GlcUA-GlcNAc repeating units.  This observation suggests that NDase does not 
distinguish between GlcUA-GlcNH2 and GlcUA-GlcNAc around the modification site.  The 
relaxed substrate specificity in the NDase domain of NDST could be one of functional 
aspects of the holoenzyme that allow for the highly and variably sulfated N-sulfo domains 
observed in naturally occurring HS and heparin structures.      
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Figure 29. Oligosaccharide profile of high pH nitrous treated NDase-treated heparosan.  Heparosan (A) 
and NDase treated heparosan (B) was deaminated at pH 4.5 which cleaves the glycosidic linkages after N-
unsubstituted glucosamine residues.   The numbers above each peak correspond to size of the eluted 
oligosaccharides (e.g. 2 for disaccharides, 4 for tetrasaccharide, etc.). The arrow indicates the end of the void 
volume.      
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Conclusions- This work demonstrates that the N-terminal domain of NDST-2 possesses N-
deacetylase activity.  Although the C-terminal domain of NDST-2 contains fully active N -
sulfotransferase activity, it has been speculated that N-deacetylase activity requires the 
participation of C-terminal residues because mutations at the C-terminal residues removed 
both N-sulfotransferase and N-deacetylase activities (Wei and Swiedler, 1999) .  Our results 
clearly demonstrate that the N-terminal domain of NDST-2 (A66-P604) carries fully 
functional N-deacetylase activity as determined by its susceptibility to NST modification and 
disaccharide analysis of NDase-treated heparosan.  Furthermore, the presence of active N-
deacetylase at the N-terminal suggests that NDST-2 contains two substrate binding sites: one 
site is located at the N-terminal for the deacetylase activity, and one is located at the C-
terminal for the N-sulfotransferase activity.  Our observed Km is slightly higher than that of 
published literature, which leads us believe that two substrate binding sites or one that 
extends into both domains, provide increased avidity to reduce the effective concentration of 
polysaccharide.  Further analysis of the NDase domain will allow us for a more 
comprehensive understanding on the mechanism of action of this important enzyme for the 
biosynthesis of heparan sulfate and heparin.
CHAPTER V. CHEMOENZYMATIC SYNTHESIS OF ANTICOAGULANT 
HEPARIN ANALOGUES
    The synthetic utility of the HS modifying enzymes has been explored in several recent 
studies.  The applicability of the sulfotransferases to remodel de-O-sulfonated heparin on the 
milligram scale suggests that the enzymes can be used to generate heparin analogues with 
distinct biological activities (Chen et al., 2005).  Additional efforts to use cheaper and readily 
available substrates are desirable. One such substrate is the capsular polysaccharide produced 
by the K5 strain of e. coli.  From the wild type strain 20-50 mg can be obtained from a one 
liter culture (unpublished data). Lindahl and co-workers have reported the expression of the 
Kfi gene cluster responsible for K5P synthesis in a common laboratory strain of e. coli that 
yielded the polysaccharide at one gram per liter (Lindahl et al., 2005).  This chapter outlines 
a methodology to produce anticoagulant heparin analogues from K5P using a 
chemoenzymatic approach.  The methodology is similar to that of (Kuberan et al., 2003b)
with several significant advancements.  The preparation of the biosynthetic enzymes is done 
in a bacterial system as opposed to baculovirus.  We report high yields of active enzyme.  
Additionally, utilization of a PAPS regeneration system should allow for the preparation of 
milligram quantities of the heparin polysaccharides.
Expression and characterization of the HS biosynthetic enzymes- Epimerase and the HS 
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sulfotransferases were expressed and purified as outlined in “METHODS”. As illustrated in 
Figure 30, the purity of MBP fusion proteins was around 60% while that of His tagged 
proteins was 90-95%.  The advantage of utilizing the MBP fusion proteins is that they 
maintain excellent solubility and could be concentrated at 4 mg/mL which facilitated enzyme 
immobilization efforts.  His tagged sulfotransferases could also be concentrated to 2-3 
mg/mL with relative ease. 
Figure 30. Expression of HS biosynthetic enzymes. The HS biosynthetic enzymes were expressed as maltose 
binding protein (MBP) or His6 fusion proteins. The affinity tags do not affect enzyme activity and were 
retained. Enzyme purity was determined by SDS-PAGE and Comassie Blue staining.  The protein bands are 
labeled for molecular weight marker (MW), Epimerase MBP (1), 2OSTHis (2), 6OSTMBP (3), 3OST1His (4).  
Purified protein yields are listed in “METHODS”
Chemical deacetylation and N sulfonation- Approximately 200 mg of K5P was prepared 
as described under in the “METHODS” chapter.  The chemical modification of the 
polysaccharide is a two step procedure that involves base catalyzed deacetylation of the 
polysaccharide followed by selective N-sulfonation using the reagent trimethylamine sulfur 
trioxide.  This synthesis was carried out in the Linhardt lab as previously described with a 
50% recovery yield (Nadkarni et al., 1996) (Munoz et al., 2006).  The resultant N-sulfo K5P 
(K5PNS) was determined to contain a small amount  5% based on a complete heparin lyase 
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digestion and disaccharide analysis as well as the radioactive N-sulfotransferase assay. From 
the disaccharide analysis in Figure 31, it appears that the chemical N-sulfonation reaction 
was regio-selective and went to > 95% completion. 
Figure 31.Structural analysis of N-sulfo K5 polysaccharide. Capsular K5 polysaccharide was chemically 
deacetylated and N-sulfonated and designated K5PNS.  K5PNS was treated with heparin lyases I, II, and III and 
subjected to reverse ion pairing HPLC. The predominant peak migrated at 15 minutes and was determined to be 
the disaccharide 4,5-unsaturated uronic acid linked to N-sulfoglucosamine (UA-GlcNS). Minor peaks at 5 and 
7 minutes reflect the solvent peak and a small degree of 4,5-unsaturated uronic acid linked to N-unsubstituted 
glucosamine.
    Size distribution and chemical degradation of the N-sulfo K5 polysaccharide- To 
determine the size distribution of the K5PNS, radiolabeled polysaccharide was subjected to 
size exclusion chromatography. A [35S] sulfuryl tag was incorporated into the polysaccharide 
by 2OST modification. The addition of the sulfuryl groups is negligible relative to the 
molecular weight of the polysaccharide based on the high specific activity donor [35S]PAPS 
(10 Ci/mmole ).  We observed a major shift in the elution profile of the K5PNS2-O-
[35S]sulfate  (Figure 32A).  This suggests that the polysaccharide underwent some 
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degradation.  Efforts to purify the lower molecular weight material proved unsuccessful 
(Figure 32B). 
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Figure 32. Size distribution of K5PNS.  K5PNS Polysaccharide chain length was determined by size 
exclusion chromatography.  K5PNS (o) was radiolabeled with high specific activity at the 2-hydroxy 
position of glucuronic acid using a high specific activity [35S]PAPS.  Metabolically labeled K5 Capsular 
polysaccharide ([3H]K5P)was run as a control (•).  The radioactive material was then eluted on a HiLoad 
Superdex 75 (Amersham) column on a FPLC system with a mobile phase of 25 mM Tris-HCl, 1000 mM 
NaCl, pH 7. Three milliliter fractions were collected and radioactive content was determined by scintillation 
counting.  Fractions 38-46 of [35S]K5PNS2S from (A) was collected and reapplied to the GPC column as the 
postfraction (o) material depicted in (B). 
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Epimerization of Capsular K5 Polysaccharide- In the next step of the synthetic route, 
K5PNS was treated with epimerase that was expressed as a maltose binding protein fusion.  
To determine the presence of IdoA in the K5PNS we used 2OST to add a radioactive tag 
[35S] sulfuryl group.  The radioactive material was then subjected to a low pH nitrous acid 
degradation followed by desalting on a P2 gel column and disaccharide analysis. As shown 
in Figure 33, it is clear that IdoA residues were indeed present in the polysaccharide.  For an 
accurate account of the percentage of IdoA in the polysaccharide, we relied on a previously 
described NMR method (Chen et al., 2005).  From this analysis, ~5% of the hexuronic acid 
residues were determined to be IdoA9. Since IdoA is essential in generating AT-binding 
heparin, a plan to generate additional IdoA residues was necessary.   
Epimerase coupled 2-O-Sulfonation- Epimerase performs a reversible conversion of GlcA 
to IdoA.  In order to drive the reaction towards the formation of IdoA, the 2OST reaction 
which preferentially generates IdoA2S over GlcA2S was coupled with epimerization in a one 
pot reaction.  Using the sulfotransferase assay to assess the benefit of a one pot strategy, with 
an excess of K5PNS, 5-6 fold more 2-O-sulfated uronic acid residues were generated with 
the addition of epimerase as shown in Figure 34. 
9
 NMR experiments were carried out in Bob Linhardt’s lab at RPI
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Figure  33. Epimerase generates IdoA residues. A qualitative analysis of epimerization of K5PNS by 
[35S]sulfo-transfer. K5PNS was incubated with epimerase as indicated in “Methods”. The epimerized 
polysaccharide was then modified with 2OST and high specific activity [35S]PAPS. The radiolabeled 
polysaccharide was then subjected to pH 1.5 nitrous degradation, desalted on a P2 gel column and the resultant 
disaccharides were analyzed by RPIP-HPLC. (1) indicates the disaccharide IdoA2S-anMan and (2) indicates 
GlcA2S-anMan.  
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Figure34. Epimerase accelerates 2-O-sulfotransfer. (A) The epimerase reaction is reversible. When coupled 
with the 2OST reaction the formation of IdoA is favored. (B) K5PNS was incubated with EPI and 2OST and 
40 µM PAP35S in a 100 µL reaction.  The amount of 2-O-sulfonation is increased by greater than five fold with 
the addition of epimerase.
    In order to determine the percentage of IdoA2S to GlcA2S in this preparation we 
performed a small scale reaction (microgram) using micromolar PAPS in addition to 
[35S]PAPS.  We coupled the EPI and 2OST reaction followed by low pH nitrous treatment 
and disaccharide analysis. Based on specific activity, an estimated four moles of sulfate was 
transferred to one mole of K5PNS.  Based on the disaccharide analysis shown in Figure 35, 
>90% of the 2-O-sulfated disaccharides were IdoA2S residues.  
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Figure 35. Coupled epimerization and 2-O-sulfonation enhances the IdoA content.  The polysaccharide 
modified with a one pot EPI/2OST was chemically degraded with nitrous acid at pH 1.5.  The resultant 
disaccharides were desalted and a disaccharide analysis was performed. From the chromatogram, approximately 
90% of the radiolabeled disaccharide was IdoA2S-anMan (1) and a small quantity of disaccharides was 
GlcA2S-anMan (2).  
    A milligram scale preparation of 2-O-sulfated K5PNS was initiated to characterize the 
material by NMR and for additional sulfo-transfer reactions.  To achieve a high degree of 
sulfation, the PAPS regeneration system was employed.  In total, the reaction requires three 
enzymes at a total protein concentration of 1-2 mg/mL.  In order to reduce the volume of the 
reaction as well as the amount of enzyme required for the preparation, 2OST was 
immobilized using the Aminolink® column. The enzyme is covalently linked to resin that 
contains activated aldehyde groups via Schiff base formation.   The Schiff base is then 
reduced to the amide with the reducing agent sodium cyanoborohydride. Under these mild 
conditions, immobilization was achieved at ~3mg protein/mL resin while retaining excellent 
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enzymatic activity10.  Approximately 2 milligrams of K5PNS2S was generated from 4 
milligrams of starting material.  A complete heparin lyase digestion resulted in 
approximately 90% digestion of the polysaccharide to disaccharide units.  RPIP-HPLC 
reveals that the polysaccharide is composed of 46% 2-O-sulfated disaccharide units (Figure 
36), while NMR data suggests that approximately 90% of the 2-O-sulfo residues are iduronic
acid (correspondence with Robert Linhardt).  
    In addition to the 46% 2-O-sulfated K5PNS (K5Hp-2), we also generated a 21% 2-O-
sulfated K5PNS (K5Hp-1), and a 10% 2-O-sulfated K5PNS.  This reduction in 2-O-sulfation 
was accessed by reducing the amount of 2OST resin and is likely dependent on the catalytic 
turnover of the enzyme.
  6-O-sulfonation of K5PNS2S- The 6OST was also expressed as a MBP fusion protein and 
immobilized as described above.  Based on radioactive the sulfotransferase reaction, 8-10 
sulfuryl groups could be transferred to one polysaccharide chain11.  Several small scale 
preparations (~10 µg) were carried out to generate K5Hp-3 (derived from 10% 2-O-sulfated 
K5PNS) and K5Hp-4 (derived from K5Hp-2). The percentages of the four major 
disaccharides resulting from heparin lyase treatment of the two preparations are listed in 
Table VI.  The additional peaks in the chromatogram could reflect some partially undigested 
materials. In order to confirm this, the peaks would have to be purified and undergo 
structural analysis.  While it is important to know the complete structure of these synthesized 
heparin analogues, a detailed structural analysis is beyond the scope of this work.
10
 The immobilized enzyme typically retains 80-90% sulfotransferase activity compared to the soluble form in a 
radioactive sulfotransfer reaction.  Chen et al. demonstrates that the immobilized enzyme retains 80% activity 
after multiple uses and is stable for approximately one month.
11
 Average length pf the polysaccharide is 40 monosaccharide units. 
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Figure 36. RPIP-HPLC chromatograms of the disaccharide analysis of EPI/2OST modified 
polysaccharides. The synthesized polysaccharides were digested with a mixture of heparin lyase I, II, and III. 
The resultant disaccharides were resolved on RPIP-HPLC. The numbers indicate the eluted positions of 
authentic disaccharide standards, where 1 represents UA-GlcNS and 2 represents UA2S-GlcNS.
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Figure 37. RPIP-HPLC chromatograms of the disaccharide analysis of EPI/2OST and 6OST modified 
polysaccharides. The synthesized polysaccharides were digested with a mixture of heparinases, including 
heparin lyase I, II, and III. The resultant disaccharides were resolved on RPIP-HPLC. The numbers indicate the 
eluted positions of authentic disaccharide standards, where 1 represents UA-GlcNS and 2 represents UA-
GlcNS6S, 3 represents UA2S-GlcNS, and 4 represents UA2S-GlcNS6S.
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Table 6. Disaccharide composition of Heparin analogues
Heparin 
analogue
UA-GlcNS UA2S-GlcNS UA-GlcNS6S UA2S-GlcNS6S
K5Hp-1 79 % 21%  
K5Hp-2 54% 46%  
K5Hp-3 73.1% 10.4% 16% 0.5%
K5Hp-4 46% 40% 13% 1%
3-O-sulfonation and anticoagulant activity of K5Hp analogues- The essential 3-O-sulfated 
glucosamine in anticoagulant heparin may be generated by 3OST1.  This 3OST isoform was 
used to radioactively label the K5Hp analogues.  These radio-labeled polysaccharides were 
then assessed for the fraction of 3-O-sulfated polysaccharide that binds to antithrombin.  This 
AT-binding assay is an excellent indicator of anticoagulant activity and indicates that the 
proper AT-binding structure of HS and heparin is present in the polysaccharide.  The relative 
binding of the 3-O-sulfated polysaccharides is presented in Figure 38.  From the graph it is 
clear that 6-O-sulfation is an important determinate for AT binding of the 3OST1 modified 
K5Hp.  K5HP-4 had the highest fraction of AT binding polysaccharide which is due to its 
total 6-O-sulfo residues and approximately 90% IdoA content (based on NMR).  These 
components coupled with the proper 3-O-sulfated glucosamine residues are critical in AT 
binding. 
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Figure 38. AT binding of heparin analogues. HS and K5Hp analogues were radio-labeled with high specific 
activity by 3OST1.  The polysaccharides were purified by DEAE anion exchange chromatography, dialyzed 
against 20 mM ammonium bicarbonate, and dried by centrifugal evaporation.  5×104 to 1×105 cpm of each of 
the samples was assessed for AT binding as described in “General Procedures”.  The negative control was 
K5NS2S radio-labeled with high specific activity PAP35S and 6OSTMBP.
Conclusions- In this chapter we report the use of a chemoenzymatic approach to generate a 
panel of heparin analogues with varying degrees of AT binding activity.  The major 
advancements of this work include the use of a PAPS regeneration system and the use of the 
K5 capsular polysaccharide as the starting material. Enhanced epimerization of the 
polysaccharide was achieved by coupling the EPI and 2OST reactions together.  Based on 
our results it is clear that in addition to a physical linkage between these two enzymes (Pinhal 
et al., 2001), it appears that there is also an important link between their activities.  The 
preferred substrate for 2OST is IdoA.  Since the epimerase reaction is reversible, the 
conversion of IdoA to IdoA2S is essential to the formation of additional IdoA residues. A 
physical linkage between these two enzymes in vivo would provide a significant advantage 
towards the formation of IdoA residues.  In addition we were able to demonstrate that the 
degree of 2-O-sulfation of the polysaccharide can be varied based on the amount of enzyme 
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that is used in the EPI/2OST reaction.  The main benefits of immobilization of the enzyme 
are that it can be recycled and is stable for up to one month at 4 °C. Enzyme immobilization 
also allows for the reduction of the reaction volume, making the purification of the modified 
polysaccharides easier.  The degradation of the K5P upon chemical deacetylation and N-
sulfonation does not appear to impact the AT-binding capacity of the heparin analogue. This 
degradation may be addressed with the use of the NDST enzyme in this approach or through 
the development of new chemical methods to modify the N position of glucosamine.
    This work provides a target structure for which the synthesis of anticoagulant heparin 
analogues can be based on.  The pursuit of multi-milligram quantities of this material is 
currently underway.   
CHAPTER VI. CONCLUSIONS
Heparin, a highly sulfated linear polysaccharide, has successfully been used in the clinic to 
treat coagulation disorders and as a prophylaxis to reduce aberrant thrombus formation 
during invasive surgeries. In addition to its use as an anticoagulant drug, a number of 
heparin and heparan sulfate (HS) analogues are currently being studied in clinical trials as 
anti-inflammatory, anti-angiogenic, and anti-metastatic agents.  Intense research interest in 
the role of HS in microbial pathogenesis is also emerging.  These studies coupled with robust 
methodologies to synthesize HS will prove useful in extending its therapeutic utility.
    The role of heparan sulfate (HS) in regulating blood coagulation has a wide range of 
clinical implications.  We investigated the role of 3-O-sulfotransferase isoform 5 (3OST5) in 
generating anticoagulant HS in vivo.  A Chinese hamster ovary cell line (3OST5/CHO) stably 
expressing 3OST5 was generated.  The expression of 3OST5 in 3OST5/CHO cells was 
confirmed by Northern analysis, RT-PCR, and the disaccharide analyses of the HS from the 
cells.  We also determined the effects of the HS from 3OST5/CHO on antithrombin-mediated 
inhibition of factor Xa.  Fluorescently labeled antithrombin bound to the surface of 
3OST5/CHO cells, suggesting that the antithrombin-binding HS is indeed present on the cell 
surface.  Our results demonstrate that the 3OST5 gene is capable of synthesizing 
anticoagulant HS in CHO cells and has the potential to contribute to the biosynthesis of 
anticoagulant HS in humans. 
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Heparan sulfate glucosaminyl N-deacetylase/N-sulfotransferase isoform 2 (NDST-2), key 
in the biosynthesis of heparin, contains two distinct activities.  This bifunctional enzyme 
removes the acetyl group from N-acetylated glucosamine (N-deacetylase activity), and 
transfers a sulfuryl group to the unsubstituted amino position (N-sulfotransferase activity).  
The N-sulfotransferases activity of NDST has been unambiguously localized to the C-
terminal domain of NDST.  Here we report that the N- terminal domain of NDST-2 retains 
N-deacetylase activity.  The N-terminal domain (A66-P604) of human NDST-2, designated 
as N-deacetylase (NDase), was cloned as a (His)6-fusion protein, and protein expression was 
carried out in E. coli.  Heparosan treated with NDase contains N-unsubstituted glucosamine 
and is highly susceptible to N-sulfation by N-sulfotransferase.  Our results conclude that the
N-terminal domain of NDST-2 contains functional N-deacetylase activity.  This finding helps 
further elucidate the mechanism of action of heparan sulfate N-deacetylase/N-
sulfotransferases and the biosynthesis of heparan sulfate in general.
   The continued development of chemical and enzymatic methods to synthesize HS and 
heparin analogues is essential to the future exploration of this biologically important 
molecule. Herein we have reported the chemoenzymatic synthesis of a variety of heparin 
analogues that differ in their ability to bind antithrombin. The analogue with the best profile 
was K5Hp-4, the most highly sulfated molecule, modified by 3OST1.  Continued efforts to 
synthesize unique heparin analogues by the use of the various HS biosynthetic enzymes 
should aid in the further development of new anticoagulant drugs as well as heparin 
molecules that can be used to treat a variety of diseases and disorders.  
103
Appendix I.
Curriculum Vitae
Michael Bernard Duncan, II
Division of Medicinal Chemistry Work: (919)962-0065
and Natural Products, CB #7360 Fax: (919)843-5432
School of Pharmacy Email: 
mbduncan@unc.edu
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599
Hometown: Ridgeland, South Carolina
Education:
University of North Carolina at Chapel Hill, 2001-present
Ph.D. Candidate, Division of Medicinal Chemistry and Natural Products 
Hampton University, 1997-2001
B.S. in Chemistry with Honors
Magna cum laude
Hampton University Honors College Graduate, 2001
Current Research Interests:
Molecular and Chemical Biology, Carbohydrate and Protein Biochemistry, Drug design: 
Protein/carbohydrate interactions; Chemoenzymatic synthesis of heparin analogs; 
Heparin/heparan sulfate biochemistry as it relates to microbial pathogenesis and 
cardiovascular biology
Publications:
1) M.B. Duncan, M. Liu, C. Fox, J. Liu. Characterization of the N-deacetylase domain from 
the heparan sulfate N-deacetylase/N-sulfotransferase 2. Biochem. Biophys. Res. Commun. 
(2006) 339:1232-7.
2) Y. Gong, M. Duvvuri, M.B. Duncan, J. Liu, J.P. Krise. Niemann-Pick C1 protein 
facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel 
vesicle-mediated pathway. J. Pharmacol. Exp. Ther. (2006) 316:242-7. 
3) M.B. Duncan, J. Chen, J.P. Krise, J. Liu. The biosynthesis of anticoagulant heparan sulfate 
by the heparan sulfate 3-O-sulfotransferase isoform 5. Biochim. et Biophys. Acta (2004) 
1671:34-43.
4) V. Tiwari, C. Clement, M.B. Duncan, J. Chen, J. Liu, D. Shukla. A role for 3-O-sulfated 
heparan in cell fusion by herpes simplex virus type 1. J Gen. Virol. (2004) 85:805-9.
104
5) J. Chen, M.B. Duncan, K. Carrick, R.M. Pope, J. Liu. Biosynthesis of 3-O-sulfated 
heparan sulfate: unique substrate specificity of heparan sulfate 3-O-sulfotransferase isoform 
5. Glycobiology (2003) 13:785-94.
6) J. Liu, Z. Shriver, R.M. Pope, S.C. Thorp, M.B. Duncan, R.J. Copeland, C.S. Raska, K. 
Yoshida, R.J. Eisenberg, G.H. Cohen, R.J. Linhardt, R. Sasisekharan. Characterization of a 
heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J 
Biol. Chem. (2002) 277:33456-67.
Patents:
J. Liu, J. Chen, M.B. Duncan, D. Shukla, V. Tiwari. Purified and isolated heparan sulfate 3-O 
sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening 
methods using the same. International Publication Number WO 2004/005475. 
Awards:
Scholar, David and Lucille Packard Foundation, 2001-06
-An award to outstanding students from Historically Black Colleges and Universities 
engaged in graduate students in the physical and life sciences. 
-$100,000 for graduate studies
Fellow, Minority and Indigenous Fellows Program, Biotechnology Institute, San Francisco 
CA, 2004
-This program pairs students, post-docs, and faculty from underserved populations at 
colleges and universities with industry mentors. Fellows are introduced to the biotechnology 
industry during the Biotechnology Institute Education Conference, where they attend 
sessions on new and emerging technologies, mentoring, and scientific content updates. 
Fellows also make field visits to local research facilities and attend the BIO Annual 
International Convention. The program continues with a year of mentoring.
American Chemical Society Hampton Roads Local Section Award for Outstanding 
Achievement 
in Chemistry, Norfolk VA, 2001
Outstanding Oral Presentation in Chemistry, 2nd Place, Beta Kappa Chi Scientific Honor 
Society 
National Conference, Atlanta GA, 2001
Scholar, Minority Access to Research Careers (MARC) Program, 1999-2001
Hampton University Presidential Scholar, 1997-2001
Undergraduate Research Experience:
105
Participant, Research Education Support Program, UNC-CH, Chapel Hill NC, Summer 2001
Advisor: Jian Liu (Medicinal Chemistry and Natural Products) 
Project: Characterization of heparan sulfate oligosaccharides by MALDI-TOF mass 
spectrometry
Participant, Summer Pre-Graduate Research Experience, UNC-CH, Morehead City NC and 
Chapel Hill NC, Summer 2000
Advisors: Neils Lindquist (Marine Sciences) and Gerhard Meissner (Biochemistry and 
Biophysics)
Project: Identification of UV absorbing compounds from the Stinker Sponge, Ircinia felix, 
that stimulate Ca2+ channels/ryanodine receptors.
Participant, Diversity Graduate Program in Science and Engineering, Rice University, 
Houston TX, Summer 1999
Advisor: W. Ed Billups (Chemistry)
Project: Synthesis and purification of substituted methylenecyclopropenes at low 
temperature. 
Participant, Summer Life Sciences Training Program, Kennedy Space Center, Cape 
Canaveral FL, Summer 1998
Advisor: Neil Yorio (Space Life Sciences) 
Project: Micronutrient deficiencies of mixed age crops in a hydroponic growth system. 
Work Experience:
Graduate Research Assistant, Division of Medicinal Chemistry, School of Pharmacy (SOP), 
University of North Carolina at Chapel Hill, 2001-current 
Thesis advisor: Jian Liu, Assistant Professor
Thesis Title: Biological and Chemoenzymatic Synthesis of Anticoagulant Heparan Sulfate
Rotation/Visiting Student Training-- Over the past year I have trained two rotating graduate 
students (Spring and Fall 2005) and two high school students (Summer 2005) working in the 
laboratory.
Instructor, PCAT preparatory course, Chemistry Section; Offered by the UNC-CH SOP 
Student National Pharmacy Association, October 2-3, 2004
I developed a lecture that served as a review of topics covered in an undergraduate general 
chemistry course.  I presented this lecture to ~100 students during a PCAT review course 
offered by the School of Pharmacy at UNC. 
Graduate Assistant, Summer Pre-Graduate Research Experience (SPGRE) Program, Summer 
2002.  
This 10 week program offers undergraduates the opportunity to perform research, take a 
GRE preparatory course, and network with a variety of scientists/scholars on the UNC-
Chapel Hill campus.  I primarily served as a group leader, directing ten students through their 
106
summer long activities.  My duties also included assisting in the organization of weekly 
seminars and a variety of administrative tasks. 
Committee/Organizational Positions Held:
Co-Chair, Invited Lecturer Series, sponsored by the Graduate Student Organization, UNC 
School of Pharmacy (SOP), 2003
Invited Speaker: Dr. Kim D. Janda, Ely R. Callaway, Jr. Professor of Chemistry, The Scripps 
Research Institute
President, UNC-SOP Graduate Student Organization, 2004-05
Committee Member, UNC-SOP Graduate Education and Research Committee, 2004-05
Ad Hoc Committee Member, UNC-SOP Graduate Program Governance Policy Committee, 
2004-05  
Committee Member, UNC-SOP Division of Medicinal Chemistry and Natural Products Chair 
Search Committee, 2004-05
Skills/Techniques
Molecular Biology
-Agarose gel electrophoresis
-Northern and Western Blotting
-Reverse Transcriptase and Real Time PCR
-Error prone PCR for random mutagenesis studies
-Various aspects of molecular cloning- Primer design, PCR, plasmid amplification/purification,
and DNA sequencing data analysis 
Biochemical/Bio-Analytical
-Bioassay development-in vitro and cell based 
-Phage display 
-ELISA
-Affinity co-electrophoresis
-Recombinant Protein expression/purification (bacterial systems)
-SDS-PAGE
-HPLC-- Ion exchange, size exclusion, reverse phase ion pairing
-FPLC-- Ion exchange, size exclusion, affinity
-Capillary electrophoresis--zone electrophoresis in normal and reverse polarity
-Chemical and enzymatic degradation of complex carbohydrates for structural analysis
-Chemical conjugation of complex glycans and glycoproteins
-Covalent Protein Immobilization
-UV Spectrophotometry--Quantitative Analysis of carbohydrates, nucleic acids, and proteins 
-Mammalian cell culture--DNA transfection, radioactive metabolic labeling of proteoglycans
-Limited exposure to Mass spectrometry- MALDI-time of flight, ESI-ion trap, MS/MS   
107
REFERENCES
Aikawa, J., Grobe, K., Tsujimoto, M., and Esko, J. D. (2001). Multiple isozymes of heparan 
sulfates/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase: Structure and activity of 
the fourth member, NDST4. J Biol Chem 276, 5876-5882.
Alvarez-Dominguez, C., Vazquez-Boland, J. A., Carrasco-Marin, E., Lopez-Mato, P., and 
Leyva-Cobian, F. (1997). Host cell heparan sulfate proteoglycans mediate attachment and 
entry of Listeria monocytogenes, and the listerial surface protein ActA is involved in heparan 
sulfate receptor recognition. Infect Immun 65, 78-88.
Angulo, J., Hricovini, M., Gairi, M., Guerrini, M., de Paz, J. L., Ojeda, R., Martin-Lomas, 
M., and Nieto, P. M. (2005). Dynamic properties of biologically active synthetic heparin-like 
hexasaccharides. Glycobiology 15, 1008-1015.
Arepally, G., and Cines, D. B. (2002). Pathogenesis of heparin-induced thrombocytopenia 
and thrombosis. Autoimmun Rev 1, 125.
Atha, D. H., Lormeau, J.-C., Petitou, M., Rosenberg, R. D., and Choay, J. (1985). 
Contribution of monosaccharide residues in heparin binding to antithrombin III. 
Biochemistry 24, 6723-6729.
Bai, X., Zhou, D., Brown, J. R., Crawford, B. E., Hennet, T., and Esko, J. D. (2001). 
Biosynthesis of the linkage region of glycosaminoglycans: cloning and activity of 
galactosyltransferase II, the sixth member of the 1,3-galactosyltransferase family 
(3GalT6). J Biol Chem 276, 48189-48195.
Bame, K. J., and Esko, J. D. (1989). Undersulfated heparan sulfate in a Chinese hamster 
ovary cell mutant defective in heparan sulfate N-sulfotransferase. J Biol Chem 264, 8059-
8065.
Bame, K. J., Lidholt, K., Lindahl, U., and Esko, J. D. (1991). Biosynthesis of heparan sulfate. 
Coordination of polymer-modification reactions in a Chinese hamster ovary cell mutant 
defective in N- sulfotransferase. J Biol Chem 266, 10287-10293.
Baraz, L., Haupt, Y., Elkin, M., Peretz, T., and Vlodavsky, I. (2006). Tumor suppressor p53 
regulates heparanase gene expression. Oncogene, in press.
Bernfield, M., Gotte, M., Park, P. W., Reizes, O., Fitzgerald, M. L., Lincecum, J., and Zako, 
M. (1999). Functions of cell surface heparan sulfate proteoglycans. Ann Rev Biochem 68, 
729-777.
Berninsone, P., and Hirschberg, C. B. (1998). Heparan sulfate/heparin N-deacetylase/N-
sulfotransferase: The N-sulfotransferase activity domain is at the carboxyl half of the 
holoenzyme. J Biol Chem 273, 25556-25559.
108
Bink, R. J., Habuchi, H., Lele, Z., Dolk, E., Joore, J., Rauch, G.-J., Geisler, R., Wilson, S. 
W., den Hertog, J., Kimata, K., and Zivkovic, D. (2003). Heparan Sulfate 6-O-
Sulfotransferase Is Essential for Muscle Development in Zebrafish. J Biol Chem 278, 31118-
31127.
Bjornsson, S. (1993). Simultaneous preparation and quantitation of proteoglycans by 
precipitation with alcian blue. Anal Biochem 210, 282-291.
Boyer, C., Wolf, M., Vedrenne, J., Meyer, D., and Larrieu, M. J. (1986). Homozygous 
variant of antithrombin III: AT III Fontainbleau. Thromb Haemost 56, 18-22.
Brinkmann, T., Weilke, C., and Kleesiek, K. (1997). Recognition of Acceptor Proteins by 
UDP-D- xylose Proteoglycan Core Protein beta -D-Xylosyltransferase. J Biol Chem 272, 
11171-11175.
Bullock, S. L., Fletcher, J. M., Beddington, R. S., and Wilson, V. A. (1998). Renal agenesis 
in mice homozygous for a gene trap mutation in the gene encoding heparan sulfate 2-
sulfotransferase. Genes Dev 12, 1894-1906.
Burkart, M. D., Izumi, M., Chapman, E., Lin, C., and Wong, C. (2000). Regeneration of 
PAPS for the enzymatic synthesis of sulfated oligosaccharides. J Org Chem 65, 5565-5574.
Capila, I., and Linhardt, R. J. (2002). Heparin-Protein Interactions. Angew Chem Int Ed 41, 
390-412.
Carfi, A., Willis, S. H., Whitbeck, J. C., Krummenacher, C., Cohen, G. H., Eisenberg, R. J., 
and Wiley, D. C. (2001). Herpes simplex virus glycoprotein D bound to the human receptor 
HveA. Mol Cell 8, 169-179.
Carter, N. M., Ali, S., and Kirby, J. A. (2003). Endothelial inflammation: the role of 
differential expression of N-deacetylase/N-sulphotransferase enzymes in alteration of the 
immunological properties of heparan sulphate. J Cell Sci 116, 3591-3600.
Carter, W. J., Cama, E., and Huntington, J. A. (2005). Crystal Structure of Thrombin Bound 
to Heparin. J Biol Chem 280, 2745 -2749.
Chapman, E., M.D., B., Hanson, S. R., and Wong, C. H. (2004). Sulfotransferases: Structure, 
mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed 43, 
3526-3548.
Chen, J., Avci, F. Y., Muñoz, E. M., McDowell, L. M., Chen, M., Pedersen, L. C., Zhang, L., 
Linhardt , R. J., and Liu, J. (2005). Enzymatically redesigning of biologically active heparan 
sulfate. J Biol Chem 280, 42817-42825.
Chen, J., Duncan, M. B., Carrick, K., Pope, M., and Liu, J. (2003). Biosynthesis of 3-O-
sulfated heparan sulfate: unique substrate specificity of heparan sulfate 3-O-sulfotransferase 
isoform 5. Glycobiology 13, 785-794.
109
Chen, J., and Liu, J. (2005). Characterization of the structure of antithrombin-binding 
heparan sulfate generated by heparan sulfate 3-O-sulfotransferase 5. Biochim Biophys Acta-
General Subjects 1725, 190.
Conrad, H. E. (1998). Heparin-binding proteins (San Diego, CA: Academic Press).
Corey, L., and Spear, P. G. (1986). Infections with herpes simplex viruses. N Engl J Med
314, 686-691 and 749-757.
Dailey, L., Ambrosetti, D., Mansukhani, A., and Basilico, C. (2005). Mechanisms underlying 
differential responses to FGF signaling. Cytokine Growth Factor Rev 16, 233.
Desai, U. R., Petitou, M., Bjork, I., and Olson, S. T. (1998). Mechanism of heparin activation 
of antithrombin.  Role of individual residues of the pentasaccharide activating sequences in 
the recognition of native and active states of antithrombin. J Biol Chem 273, 7478-7487.
Duensing, T. D., and Putten, J. P. (1998). Vitronectin binds to the gonococcal adhesin OpaA 
through a glycosaminoglycan molecular bridge. Biochem J 334, 133-139.
Duensing, T. D., Wing, J. S., and van Putten, J. P. M. (1999). Sulfated Polysaccharide-
Directed Recruitment of Mammalian Host Proteins: a Novel Strategy in Microbial 
Pathogenesis. Infect Immun 67, 4463-4468.
Edavettal, S. C., Lee, K. A., Negishi, M., Linhardt, R. J., Liu, J., and Pedersen, L. C. (2004). 
Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J 
Biol Chem 279, 25789-25797.
Eriksson, I., Sanback, D., Ek, B., Lindahl, U., and Kjellen, L. (1994). cDNA cloning and 
sequencing of mouse mastocytoma glucosaminyl N- deacetylase/N-sulfotransferase, an 
enzyme involved in the biosynthesis of heparin. J Biol Chem 269, 10438-10443.
Esko, J. D., and Selleck, S. B. (2002). Order out of chaos: Assembly of ligand binding sites 
in heparan sulfate. Ann Rev Biochem 71, 435-471.
Esko, J. D., Stewart, T. E., and Taylor, W. H. (1985). Animal Cell Mutants Defective in 
Glycosaminoglycan Biosynthesis. Proc Natl Acad Sci 82, 3197-3201.
Faham, S., Hileman, R. E., Fromm, J. R., Linhardt, R. J., and Rees, D. C. (1996). Heparin 
structure and interactions with basic fibroblast growth factor. Science 271, 1116-1120.
Fan, G., Xiao, L., Cheng, L., Wang, X., Sun, B., and Hu, G. (2000). Targeted disruption of 
NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS 
Lett 467, 7-11.
110
Forsberg, E., Pejler, G., Ringvall, M., Lunderius, C., Tomasini-Johansson, B., Kusche-
Gullberg, M., Eriksson, I., Ledin, J., Hellman, L., and Kjellen, L. (1999). Abnormal mast 
cells in mice deficient in a heparin-synthesizing enzyme. Nature 400, 773-776.
Frevert, C. W., Kinsella, M. G., Vathanaprida, C., Goodman, R. B., Baskin, D. G., Proudfoot, 
A., Wells, T. N. C., Wight, T. N., and Martin, T. R. (2003). Binding of Interleukin-8 to 
Heparan Sulfate and Chondroitin Sulfate in Lung Tissue. Am J Respir Cell Mol Biol 28, 464-
472.
Gama, C. I., and Hsieh-Wilson, L. C. (2005). Chemical approaches to deciphering the 
glycosaminoglycan code. Curr Opin Chem Biol 9, 609.
Gan, Z. R., Li, Y., Chen, Z., Lewis, S. D., and Shafer, J. A. (1994). Identification of basic 
amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin 
III. J Biol Chem 269, 1301-1305.
Girardin, E. P., HajMohammadi, S., Birmele, B., Helisch, A., Shworak, N. W., and de 
Agostini, A. I. (2005). Synthesis of Anticoagulantly Active Heparan Sulfate Proteoglycans 
by Glomerular Epithelial Cells Involves Multiple 3-O-Sulfotransferase Isoforms and a 
Limiting Precursor Pool. J Biol Chem 280, 38059-38070.
Gómez-Duarte, O. G., Dehio, M., Guzmán, C. A., Chhatwal, G. S., Dehio, C., and Meyer, T. 
F. (1997). Binding of vitronectin to opa-expressing Neisseria gonorrhoeae mediates invasion 
of HeLa cells. Infect Immun 65, 3857-3866.
Gotte, M. (2003). Syndecans in inflammation. FASEB J 17, 575-591.
Gotting, C., Kuhn, J., Zahn, R., Brinkmann, T., and Kleesiek, K. (2000). Molecular cloning 
and expression of human UDP-d-Xylose:proteoglycan core protein beta-d- xylosyltransferase 
and its first isoform XT-II. J Mol Biol 304, 517-528.
Gotting, C., Sollberg, S., Kuhn, J., Weilke, C., Huerkamp, C., Brinkmann, T., Krieg, T., and 
Kleesiek, K. (1999). Serum xylosyltransferase: a new biochemical marker of the sclerotic 
process in systemic sclerosis. J Invest Derm 112, 919.
Grobe, K., and Esko, J. D. (2002). Regulated translation of heparan sulfate GlcNAc N-
deacetylase/N-sulfotransferase isozymes by structured 5'-untranslated regions and internal 
ribosome entry sites. J Biol Chem 277, 30699-30706.
Gulberti, S., Lattard, V., Fondeur, M., Jacquinet, J.-C., Mulliert, G., Netter, P., Magdalou, J., 
Ouzzine, M., and Fournel-Gigleux, S. (2005). Phosphorylation and Sulfation of 
Oligosaccharide Substrates Critically Influence the Activity of Human {beta}1,4-
Galactosyltransferase 7 (GalT-I) and {beta}1,3-Glucuronosyltransferase I (GlcAT-I) 
Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of 
Proteoglycans. J Biol Chem 280, 1417-1425.
111
Habuchi, H., Miyake, G., Nogami, K., Kuroiwa, A., Matsuda, Y., Kusche-Gullberg, M., 
Habuchi, O., Tanaka, M., and Kimata, K. (2003). Biosynthesis of heparan sulphate with 
diverse structures and functions: two alternatively spliced forms of human heparan sulphate 
6-O-sulphotransferase-2 having different expression patterns and properties. Biochem J 371, 
131-142.
Habuchi, H., Tanaka, M., Habuchi, O., Yoshida, K., Suzuki, H., Ban, K., and Kimata, K. 
(2000). The occurance of three isoforms of heparan sulfate 6-O-sulfotransferase having 
different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine. J Biol 
Chem 275, 2859-2868.
Hacker, U., Nybakken, K., and Perrimon, N. (2005). HEPARAN SULPHATE 
PROTEOGLYCANS: THE SWEET SIDE OF DEVELOPMENT. Nature Rev Mol Cell Biol
6, 530.
Hagner-McWhirter, A., Li, J., Oscarson, S., and Lindahl, U. (2004). Irreversible glucuronyl 
C5-epimerization in the biosynthesis of heparan sulfate. J Biol Chem 279, 14631-14638.
Hagner-Mcwhirter, A., Lindahl, U., and Li, J. (2000). Biosynthesis of heparin/heparan 
sulphate: mechanism of epimerization of glucuronyl C-5. Biochem J 347, 69-75.
HajMohammadi, S., Enjyoji, K., Princivalle, M., Christi, P., Lech, M., Beeler, D. L., 
Rayburn, H., Schwartz, J. J., Barzegar, S., de Agostini, A. I., et al. (2003). Normal levels of 
anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest 111, 989-
999.
Handel, T. M., Johnson, Z., Crown, S. E., Lau, E. K., Sweeney, M., and Proudfoot, A. E. 
(2005). REGULATION OF PROTEIN FUNCTION BY GLYCOSAMINOGLYCANS AS 
EXEMPLIFIED BY CHEMOKINES. Ann Rev of Biochem 74, 385-410.
Holmborn, K., Ledin, J., Smeds, E., Eriksson, I., Kusche-Gullberg, M., and Kjellen, L. 
(2004). Heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and 
NDST2 is 6-O-sulfated but contains no N-sulfate groups. J Biol Chem 279, 42355-42358.
Hoogewerf, A. J., Kuschert, G. S. V., Proudfoot, A. E. I., Borlat, F., Clark-Lewis, I., Power, 
C. A., and Wells, T. N. C. (1997). Glycosaminoglycans Mediate Cell Surface 
Oligomerization of Chemokines. Biochemistry 36, 13570-13578.
Hovingh, P., and Linker, A. (1970). The Enzymatic Degradation of Heparin and Heparitin 
Sulfate. III. PURIFICATION OF A HEPARITINASE AND A HEPARINASE FROM 
FLAVOBACTERIA. J Biol Chem 245, 6170-6175.
Hricovini, M., Guerrini, M., Bisio, A., Torri, G., Petitou, M., and Casu, B. (2001). 
Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J 359, 265-
272.
112
Hulett, M. D., Freeman, C., Hamdorf, B. J., Baker, R. T., Harris, M. J., and Parish, C. R. 
(1999). Cloning of mammalian heparanase, an important enzyme in tumor invasion and 
metastasis. Nat Med 5, 803-809.
Huntington, J. A. (2005). Molecular recognition mechanisms of thrombin. J Throm Haemos
3, 1861-1872.
Iozzo, R. V. (2005). BASEMENT MEMBRANE PROTEOGLYCANS: FROM CELLAR 
TO CEILING. Nature Rev Mol Cell Biol 6, 646.
Jin, L., Abrahams, P., Skinner, R., Petitou, M., Pike, R. N., and Carrell, R. W. (1997). The 
anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci 94, 14683-14688.
Johnson, D. J., and Huntington, J. A. (2003). Crystal structure of antithrombin in a heparin-
bound intermediate state. Biochemistry 42, 8712-8719.
Joyce, J. A., Freeman, C., Meyer-Morse, N., Parish, C. R., and Hanahan, D. (2005). A 
functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor 
angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24, 4037-4051.
Kakuta, Y., Li, L., Pedersen, L. C., Pedersen, L. G., and Negishi, M. (2003). Heparan 
sulphate N-sulphotransferase activity: reaction mechanism and substrate recognition. 
Biochem Soc Trans 31 (pt2), 331-334.
Kakuta, Y., Sueyoshi, T., Negishi, M., and Pedersen, L. C. (1999). Crystal structure of the 
sulfotransferase domain of human heparan sulfate N-deacetylase/N-sulfotransferase 1. J Biol 
Chem 274, 10673-10676.
Kearns, A. E., Vertel, B. M., and Schwartz, N. B. (1993). Topography of glycosylation and 
UDP-xylose production. J Biol Chem 268, 11097-11104.
Kelly, T., Miao, H. Q., Yang, Y., Navarro, E., Kussie, P., Huang, Y., MacLeod, V., 
Casciano, J., Joseph, L., Zhan, F., et al. (2003). High heparanase activity in multiple 
myeloma is associated with elevated microvessel density. Cancer Res 63, 8749-8756.
Kim, A. W., Xu, X., Hollinger, E. F., Gattuso, P., Godellas, C. V., and Prinz, R. A. (2002). 
Human Heparanase-1 Gene Expression in Pancreatic Adenocarcinoma. J Gastro Surgery 6, 
167-172.
Kim, B.-T., Kitagawa, H., Tanaka, J., Tamura, J.-i., and Sugahara, K. (2003). In Vitro 
Heparan Sulfate Polymerization: CRUCIAL ROLES OF CORE PROTEIN MOIETIES OF 
PRIMER SUBSTRATES IN ADDITION TO THE EXT1-EXT2 INTERACTION. J Biol 
Chem 278, 41618-41623.
Kitagawa, H., Tone, Y., Tamura, J.-i., Neumann, K. W., Ogawa, T., Oka, S., Kawasaki, T., 
and Sugahara, K. (1998). Molecular Cloning and Expression of Glucuronyltransferase I 
113
Involved in the Biosynthesis of the Glycosaminoglycan-Protein Linkage Region of 
Proteoglycans. J Biol Chem 273, 6615-6618.
Kobayashi, M., Habuchi, H., Habuchi, O., Saito, M., and Kimata, K. (1996). Purification and 
characterization of heparan sulfate 2-sulfotransferase from cultured Chinese hamster ovary 
cells. J Biol Chem 271, 7645-7653.
Kobayashi, S.-i., Morimoto, K.-i., Shimizu, T., Takahashi, M., Kurosawa, H., and Shirasawa, 
T. (2000). Association of EXT1 and EXT2, Hereditary Multiple Exostoses Gene Products, in 
Golgi Apparatus. Biochem Biophys Res Commun 268, 860.
Koide, T., Odani, S., Takahashi, K., Ono, T., and Sakuragawa, N. (1984). Antithrombin III 
Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that 
lacks heparin-binding ability. Proc Natl Acad Sci USA 81, 289-293.
Kraulis, P. J. (1991). MOLSCRIPT:  a program to produce both detailed and schematic plots 
of protein structures. J Appl Crystallogr 24, 946-950.
Kuberan, B., Beeler, D. L., Lawrence, R., Lech, M., and Rosenberg, R. (2003a). Rapid two-
step synthesis of mitrin from heparosan: a replacement for heparin. J Am Chem Soc 125, 
12424-12425.
Kuberan, B., Beeler, D. L., Lech, M., Wu, Z. L., and Rosenberg, R. D. (2003b). 
Chemoenzymatic Synthesis of Classical and Non-classical Anticoagulant Heparan Sulfate 
Polysaccharides. J Biol Chem 278, 52613-52621.
Kuberan, B., Lech, M. Z., Beeler, D. L., Wu, Z. L., and Rosenberg, R. D. (2003c). Enzymatic 
synthesis of antithrombin III-binding heparan sulfate pentasaccharide. Nat Biotech 21, 1343.
Kusche-Gullberg, M., and Kjellen, L. (2003). Sulfotransferases in glycosaminoglycan 
biosynthesis. Curr Opin Struct Biol 13, 605.
Kuschert, G. S. V., Coulin, F., Power, C. A., Proudfoot, A. E. I., Hubbard, R. E., Hoogewerf, 
A. J., and Wells, T. N. C. (1999). Glycosaminoglycans Interact Selectively with Chemokines 
and Modulate Receptor Binding and Cellular Responses. Biochemistry 38, 12959-12968.
Ledin, J., Staatz, W., Li, J.-P., Gotte, M., Selleck, S. B., Kjellen, L., and Spillmann, D. 
(2004). Heparan sulfate structure in mice with genetically modified heparan sulfate 
production. J Biol Chem 279, 42732-42741.
Lee, M. K., and Lander, A. D. (1991). Analysis affinity and strutural selectivity in the 
binding of proteins to glycosamineglycans: Development of a sensitive electrophoretc 
approach. Proc Natl Acad Sci USA 88, 2768-2772.
Lever, R., and Page, C. P. (2002). Novel drug development opportunity for heparin. Nat Rev
1, 140-148.
114
Li, J.-P., Gong, F., Hagner-McWhirter, A., Forsberg, E., Åbrink, M., Kisilevsky, R., Zhang, 
X., and Lindahl, U. (2003). Targeted disruption of a murine glucuronyl C5- epimerase gene 
results in heparan sulfate lacking L-iduronic acid and in neonatal lethality. J Biol Chem 278, 
28363-28366.
Li, Q., Park, P. W., Wilson, C. L., and Parks, W. C. (2002). Matrilysin shedding of syndecan-
1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung 
injury. Cell 111, 635-646.
Lind, T., Lindahl, U., and Lidholt, K. (1993). Biosynthesis of heparin/heparan sulfate. 
Identification of a 70-kDa protein catalyzing both the D-glucuronosyl- and the N-acetyl-D-
glucosaminyltransferase reactions. J Biol Chem 268, 20705.
Lindahl, U., Li, J., Kusche-Gullberg, M., Salmivirta, M., Alaranta, S., Veromaa, T., Emies, 
J., Roberts, I., Taylor, C., Oreste, P., et al. (2005). Generation of "neoheparin" from E. Coli
K5 capsular polysaccharide. J Med Chem 48, 349-352.
Linhardt, R. J. (2003). 2003 Claude S. Hudson Award address in carbohydrate chemistry. 
Heparin: structure and activity. J Med Chem 46, 2551-2564.
Liu, J., and Rosenberg, R. D. (2002). Heparan sulfate D-glucosaminyl 3-O-sulfotransferase, 
In Handbook of glycosyltransferases and their related genes, N. Taniguchi, and M. Fukuda, 
eds. (Tokyo: Springer-Verlag), pp. 475-483.
Liu, J., Shriver, Z., Pope, R. M., Thorp, S. C., Duncan, M. B., Copeland, R. J., Raska, C. S., 
Yoshida, K., Eisenberg, R. J., Cohen, G., et al. (2002). Characterization of a heparan sulfate 
octasaccharide that binds to herpes simplex viral type 1 glycoprotein D. J Biol Chem 277, 
33456-33467.
Liu, J., Shworak, N. W., Fritze, L. M. S., Edelberg, J. M., and Rosenberg, R. D. (1996).
Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem 271, 
27072-27082.
Liu, J., Shworak, N. W., Sinaÿ, P., Schwartz, J. J., Zhang, L., Fritze, L. M. S., and 
Rosenberg, R. D. (1999). Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase 
isoforms reveals novel substrate specificities.  J Biol Chem 274, 5185-5192.
Liu, J., and Thorp, S. C. (2002). Heparan sulfate and the roles in assisting viral infections. 
Med Res Rev 22, 1-25.
Lohse, D. L., and Linhardt, R. J. (1992). Purification and characterization of heparin lyases 
from Flavobacterium heparinum. J Biol Chem 267, 24347-24355.
Lyon, M., Rushton, G., Askari, J. A., Humphries, M. J., and Gallagher, J. T. (2000). 
Elucidation of the structural features of heparan sulfate important for interaction with the 
Hep-2 domain of fibronectin. J Biol Chem 275, 4599-4606.
115
Maxhimer, J. B., Quiros, R. M., Stewart, R., Dowlatshahi, K., Gattuso, P., Fan, M., Prinz, R. 
A., and Xu, X. (2002). Heparanase-1 expression is associated with the metastatic potential of 
breast cancer. Surgery 132, 326-333.
McCormick, C., Duncan, G., Goutsos, T., and Tufaro, F. (2000). The putative tumor 
suppressos EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus 
and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci 97, 668-673.
McKeehan, W. L., Wu, X., and Kan, M. (1999). Requirement for anticoagulant heparan 
sulfate in the fibroblast growth factor receptor complex. J Biol Chem 274, 21511-21514.
Merritt, E. A., and Bacon, D. J. (1997). Raster3D:  Photorealistic molecular graphics. Meth 
Enz 277, 505-524.
Middleton, J., Neil, S., Wintle, J., Clark-Lewis, I., Moore, H., Lam, C., Auer, M., Hub, E., 
and Rot, A. (1997). Transcytosis and Surface Presentation of IL-8 by Venular Endothelial 
Cells. Cell 91, 385.
Mikhailov, D., Young, H. C., Linhardt, R. J., and Mayo, K. H. (1999). Heparin 
Dodecasaccharide Binding to Platelet Factor-4 and Growth-related Protein-alpha. J Biol 
Chem 274, 25317-25329.
Mochizuki, H., Yoshida, K., Gotoh, M., Sugioka, S., Kikuchi, N., Kwon, Y.-D., Tawada, A., 
Maeyama, K., Inaba, N., Hiruma, T., et al. (2003). Characterization of a heparan sulfate 3-O-
sulfotransferase-5 an enzyme synthesizing a tetrasulfated disaccharide. J Biol Chem 278, 
26780-26787.
Mohammadi, M., Olsen, S. K., and Goetz, R. (2005a). A protein canyon in the FGF-FGF 
receptor dimer selects from an a la carte menu of heparan sulfate motifs. Curr Opin Struct 
Biol 15, 506-516.
Mohammadi, M., Olsen, S. K., and Ibrahimi, O. A. (2005b). Structural basis for fibroblast 
growth factor receptor activation. Cytokine Growth Factor Rev 16, 107-137.
Moon, A., Edavettal, S. C., Krahn, J. X., Munoz, E. M., Negishi, M., Linhardt, R. J., Liu, J., 
and Pedersen, L. C. (2004). Structural analysis of the sulfotransferase (3-OST-3) involved in 
the biosynthesis of an entry receptor of herpes simplex virus 1. J Biol Chem 279, 45185-
45193.
Motowo Nakajima, T. I. G. L. N. (1988). Heparanases and tumor metastasis. J Cell Biochem
36, 157-167.
Mulloy, B., Forster, M. J., Jones, C., and Davies, D. B. (1993). N.m.r. and molecular-
modelling studies of the solution conformation of heparin. Biochem J 293, 849–858.
116
Munoz, E., Xu, D., Avci, F., Kemp, M., Liu, J., and Linhardt, R. J. (2006). Enzymatic 
synthesis of heparin related polysaccharides on sensor chips: Rapid screening of heparin-
protein interactions. Biochem Biophys Res Commun 339, 597.
Nadkarni, V. D., Toida, T., Van Gorp, C. L., Schubert, R. L., Weiler, J. M., Hansen, K. P., 
Caldwell, E. E. O., and Linhardt, R. J. (1996). Preparation and biological activity of N-
sulfonated chondroitin and dermatan sulfate derivatives. Carbohydrate Res 290 , 87.
Noti, C., and Seeberger, P. H. (2005). Chemical Approaches to Define the Structure-Activity 
Relationship of Heparin-like Glycosaminoglycans. Chem Biol 12, 731.
Okajima, T., Yoshida, K., Kondo, T., and Furukawa, K. (1999). Human Homolog of 
Caenorhabditis elegans sqv-3 Gene Is Galactosyltransferase I Involved in the Biosynthesis of 
the Glycosaminoglycan-Protein Linkage Region of Proteoglycans. J Biol Chem 274 , 22915-
22918.
Orellana, A., Hirschberg, C. B., Wei, Z., Swiedler, S. J., and Ishihara, M. (1994). Molecular 
cloning and expression of a glycosaminoglycan N- acetylglucosaminyl N-deacetylase/N-
sulfotransferase from a heparin- producing cell line. J Biol Chem 269, 2270-2276.
Park, P. W., Foster, T. J., Nishi, E., Duncan, S. J., Klagsbrun, M., and Chen, Y. (2004). 
Activation of Syndecan-1 Ectodomain Shedding by Staphylococcus aureus {alpha}-Toxin 
and {beta}-Toxin. J Biol Chem 279, 251-258.
Park, P. W., Pier, G. B., Hinkes, M. T., and Bernfield, M. (2001). Exploitation of syndecan-1 
shedding by Pseudomonas aeruginosa enhances virulence. Nature 411, 98-102.
Park, P. W., Pier, G. B., Preston, M. J., Goldberger, O., Fitzgerald, M. L., and Bernfield, M. 
(2000a). Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of 
pseudomonas aeruginosa. J Biol Chem 275, 3057-3064.
Park, P. W., Reizes, O., and Bernfield, M. (2000b). Cell surface heparan sulfate 
proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem 275, 29923-
29926.
Pellegrini, L., Burke, D. F., von Delft, F., Mulloy, B., and Blundell, T. L. (2000). Crystal 
structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature
407, 1029.
Petitou, M., Duchaussoy, P., Lederman, I., Choay, J., Sinay, P., Jacquinet, J.-C., and Torri, 
G. (1986). Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-
deoxy-2-sulfamido-6-O-sulfo-[alpha]--glucopyranosyl)-(1-->4)-O-([beta]--
glucopyranosyluronic acid)-(1-->4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-[alpha]--
glucopyranosyl)-(1-->4)-O-(2-O-sulfo- [alpha]--idopyranosyluronic acid)-(1-->4)-2-deoxy-2-
sulfamido-6-O-sulfo-- glucopyranose decasodium salt, a heparin fragment having high 
affinity for antithrombin III. Carbohydrate Res 147 , 221-236.
117
Pinhal, M. A., Smith, B., Olson, S., Aikawa, J., Kimata, K., and Esko, J. D. (2001). Enzyme 
interactions in heparan sulfate biosynthesis: uronosyl 5-epimerase and 2-O-sulfotransferase 
interact in vivo. Proc Natl Acad Sci 98, 12984-12989.
Pye, D. A., Vives, R. R., Turnbull, J. E., Hyde, P., and Gallagher, J. T. (1998). Heparan 
sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor 
mitogenic activity. J Biol Chem 273, 22936-22942.
Rapraeger, A. C., Krufka, A., and Olwin, B. B. (1991). Requirement of heparan sulfate for 
bFGF-mediated fibroblast growth and myoblast differentiation. Science 252, 1705-1708.
Quiros, R. M., Rao, G., Plate, J ., Harris, J. E., Brunn, G. J., Platt, J. L., Gattuso, P., Prinz, R.
A., Xu, X.  (2006). Elevated serum heparanase-1 levels in patients with pancreatic carcinoma 
are associated with poor survival. Cancer 106, 532-540.
Rong, J., Habuchi, H., Kimata, K., Lindahl, U., and Kusche-Gullberg, M. (2001). Substrate 
specificity of the heparan sulfate hexuronic acid 2-O-sulfotransferase. Biochemistry 40, 
5548-5555.
Rosenberg, R. D., Oosta, G. M., Jordan, R. E., and Gardner, W. T. (1980). The interaction of 
heparin with thrombin and antithrombin. Biochem Biophys Res Commun 96, 1200-1208.
Rosenberg, R. D., Showrak, N. W., Liu, J., Schwartz, J. J., and Zhang, L. (1997). Heparan 
sulfate proteoglycans of the cardiovascular system: specific structures emerge but how is 
synthesis regulated? J Clin Invest 99, 2062-2070.
Sadir, R., Imberty, A., Baleux, F., and Lortat-Jacob, H. (2004). Heparan Sulfate/Heparin 
Oligosaccharides Protect Stromal Cell-derived Factor-1 (SDF-1)/CXCL12 against 
Proteolysis Induced by CD26/Dipeptidyl Peptidase IV. J Biol Chem 279, 43854-43860.
Saribas, A. S., Mobasseri, A., Pristatsky, P., Chen, X., Barthelson, R., Hakes, D., and Wang, 
J. (2004). Production of N-sulfated polysaccharides using yeast expressed N-deacetylase/N-
sulfotransferase-1 (NDST-1). Glycobiology 14, 1217-1228.
Sasisekharan, R., Shriver, Z., Venkataraman, G., and Narayanasami, U. (2002). Roles of 
heparin-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2, 521-528.
Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, 
A., Linhardt , R. J., and Mohammadi, M. (2000). Crystal structure of a ternary FGF-FGFR-
heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell
6, 743-750.
Sheehan, J. P., and Sadler, J. E. (1994). Molecular Mapping of the Heparin-Binding Exosite 
of Thrombin. Proc Natl Acad Sci 91, 5518-5522.
118
Sheng, J. J., Saxena, A., and Duffel, M. W. (2004). Influence of phenylanalines 77 and 138 
on the stereospecificity of arylsulfotransferase IV. Drug Metabol Dispost 32, 559-565.
Shively, J. E., and Conrad, H. E. (1976). Formation of anhydrosugars in the chemical 
depolymerization of heparin. Biochemistry 15, 3932-3942.
Shukla, D., Liu, J., Blaiklock, P., Shworak, N. W., Bai, X., Esko, J. D., Cohen, G. H., 
Eisenberg, R. J., Rosenberg, R. D., and Spear, P. G. (1999). A novel role for 3-O-sulfated 
heparan sulfate in herpes simplex virus 1 entry. Cell 99, 13-22.
Shukla, D., and Spear, P. G. (2001). Herpesviruses and heparan sulfate: an intimate 
relationship in aid of viral entry. J Clin Invest 108, 503-510.
Shworak, N. W., Liu, J., Fritze, L. M. S., Schwartz, J. J., Zhang, L., Logeart, D., and 
Rosenberg, R. D. (1997). Molecular cloning and expression of mouse and human cDNAs 
encoding heparan sulfate D-glucosaminyl 3-O-sulfotransferase. J Biol Chem 272, 28008-
28019.
Shworak, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, 
N. A., and Rosenberg, R. D. (1999). Diversity of the extensive heparan sulfate D-
glucosaminyl 3-O-sulfotransferase (3-OST) multigene family. J Biol Chem 274, 5170-5184.
Simizu, S., Ishida, K., and Osada, H. (2004). Heparanase as a molecular target of cancer 
chemotherapy. Cancer Science 95, 553-558.
Slungaard, A. (2005). Platelet factor 4: a chemokine enigma. Inter J Biochem Cell Biol 37, 
1162.
Smeds, E., Habuchi, H., Do, A.-T., Hjertson, E., Grundberg, H., Kimata, K., Lindahl, U., and 
Kusche-Gullberg, M. (2003). Substrate specificities of mouse heparan sulphate glucosaminyl 
6-O-sulfotransferases. Biochem J 372 (pt2), 371-380.
Spear, P. G. (2004). Herpes simplex virus: receptors and ligands for cell entry. Cellular 
Microbiol 6, 401-410.
Spear, P. G., Eisenberg, R. J., and Cohen, G. H. (2000). Three classes of cell surface 
receptors for alphaherpesvirus entry. Virology 275, 1-8.
Spillmann, D., Witt, D., and Lindahl, U. (1998). Defining the Interleukin-8-binding Domain 
of Heparan Sulfate. J Biol Chem 273, 15487-15493.
Stringer, S. E., Forster, M. J., Mulloy, B., Bishop, C. R., Graham, G. J., and Gallagher, J. T. 
(2002). Characterization of the binding site on heparan sulfate for macrophage inflammatory 
protein 1alpha. Blood 100, 1543-1550.
Stringer, S. E., and Gallagher, J. T. (1997). Specific binding of the chemokin platelet factor 4 
to heparan sulfate. J Biol Chem 272 , 20508-20514.
119
Sugahara, K., and Kitagawa, H. (2002). Heparin and Heparan Sulfate Biosynthesis. IUBMB 
Life 54, 163-175.
Sundaram, M., Qi, Y., Shriver, Z., Liu, D., Zhao, G., Venkataraman, G., Langer, R., and 
Sasisekharan, R. (2003). Rational design of low-molecular weight heparins with improved in 
vivo activity. Proc Natl Acad Sci 100, 651-656.
Taraktchoglou, M., Pacey, A. A., Turnbull, J. E., and Eley, A. (2001). Infectivity of 
Chlamydia trachomatis Serovar LGV but Not E Is Dependent on Host Cell Heparan Sulfate. 
Infect Immun 69, 968-976.
Tonnaer, E. L. G. M., Hafmans, T. G., Van Kuppevelt, T. H., Sanders, E. A. M., Verweij, P. 
E., and Curfs, J. H. A. J. (2006). Involvement of glycosaminoglycans in the attachment of 
pneumococci to nasopharyngeal epithelial cells. Microbes and Infection 8, 316.
Ueno, M., Yamada, S., Zako, M., Bernfield, M., and Sugahara, K. (2001). Structural 
Characterization of Heparan Sulfate and Chondroitin Sulfate of Syndecan-1 Purified from 
Normal Murine Mammary Gland Epithelial Cells. COMMON PHOSPHORYLATION OF 
XYLOSE AND DIFFERENTIAL SULFATION OF GALACTOSE IN THE PROTEIN 
LINKAGE REGION TETRASACCHARIDE SEQUENCE. J Biol Chem 276, 29134-29140.
van Boven, H. H., and Lane, D. A. (1997). Antithrombin and its inherited deficiency states. 
Semin Hematol 34, 188-204.
Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, 
M., Pappo, O., Peretz, T., Michal, I., et al. (1999). Mammalian heparanase: Gene cloning, 
expression and function in tumor progression and metastasis. Nat Med 5, 793-802.
Wadstrom, T., and Ljungh, A. (1999). Glycosaminoglycan-binding microbial proteins in 
tissue adhesion and invasion: key events in microbial pathogenicity. J Med Microbiol 48, 
223-233.
Wang, L., Fuster, M., Sriramarao, P., and Esko, J. D. (2005). Endothelial heparan sulfate 
deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during 
inflammatory responses. Nat Immunol 6, 902.
Wei, G., Bai, X., Gabb, M. M., Bame, K. J., Koshy, T. I., Spear, P. G., and Esko, J. D. 
(2000). Location of the glucuronosyltransferase domain in the heparan sulfate copolymerase 
EXT1 by analysis of Chinese hamster ovary cell mutants. J Biol Chem 275, 27733.
Wei, Z., and Swiedler, S. J. (1999). Functional analysis of conserved cysteines in heparan 
sulfate N-deacetylase-N-sulfotransferases. J Biol Chem 274, 1966-1970.
Wu, Z. L., Lech, M., Beeler, D. L., and Rosenberg, R. D. (2004). Determining heparan 
sulfate structure in the vicinity of specific sulfotransferase recognition sites by mass 
spectrometry. J Biol Chem 279, 1861-1866.
120
Xia, G., Chen, J., Tiwari, V., Ju, W., Li, J.-P., Malmström, A., Shukla, D., and Liu, J. (2002). 
Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site 
and an entry receptor for herpes simplex virus, type 1. J Biol Chem 277, 37912-37919.
Xu, D., Tiwari, V., Xia, G., Clement, C., Shukla, D., and Liu, J. (2005). Characterization of 
Heparan Sulfate 3-O-Sulfotransferase Isoform 6 and Its Role in Assisting the Entry of Herpes 
Simplex Virus, Type 1. Biochem J 385, 451-459.
Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P., and Ornitz, D. M. (1991). Cell surface, 
heparin-like molecules are required for binding of basic fibroblast growth factor to its high 
affinity receptor. Cell 64, 841-848.
Ye, J., Rezaie, A. R., and Esmon, C. T. (1994). Glycosaminoglycan contributions to both 
protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin 
that includes residues arginine 93, 97, and 101. J Biol Chem 269, 17965-17970.
Yoon, M., and Spear, P. G. (2004). Random mutagenesis of the gene encoding a viral ligand 
for multiple cell entry receptors to obtain viral mutants altered for receptor usage. Proc Natl 
Acad Sci 101, 17252-17257.
Yoon, M., Zago, A., Shukla, D., and Spear, P. G. (2003). Mutations in the N-termini of 
herpes simplex virus type 1 and 2 gDs alter functional interactions with the entry/fusion 
receptors HVEM, Nectin-2, and 3-O-sulfated heparan sulfate but not with Nectin-1. J Virol
77, 9221-9231.
Zak, B. M., Crawford, B. E., and Esko, J. D. (2002). Hereditary multiple exostoses and 
heparan sulfate polymerization. Biochim Biophys Acta- General Subjects 1573, 346-355.
Zhang, L., Beeler, D. L., Lawrence, R., Lech, M., Liu, J., Davis, J. C., Shriver, Z., 
Sasisekharan, R., and Rosenberg, R. D. (2001a). 6-O-sulfotransferase-1 represents a critical 
enzyme in the anticoagulant heparan sulfate biosynthetic pathway. J Biol Chem 276, 42311-
42321.
Zhang, L., Lawrence, R., Schwartz, J. J., Bai, X., Wei, G., Esko, J. D., and Rosenberg, R. D. 
(2001b). The effect of precursor structures on the action of glucosaminyl 3-O-
sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate. J Biol Chem 276, 
28806-28813.
Zhang, L., Schwartz, J. J., Miller, J., Liu, J., Fritze, L. M. S., Shworak, N. W., and 
Rosenberg, R. D. (1998). The retinoic acid and cAMP-dependent up-regulation of 3-O-
sulfotransferase-1 leads to a dramatic augmentation of anticoagulantly active heparan sulfate 
biosynthesis in F9 embryonal carcinoma cells. J Biol Chem 273, 27998-28003.
